Cover Page  
Official title:  A Randomised, Double -blind, Placebo -controlled Trial to Evaluate the Effect of  
Tralokinumab on Vaccine Antibody Responses in Adults With Moderate -to-severe Atopic Dermatitis Who 
Are Candidates for Systemic Therapy  
LEO Pharma number:  LP016 2-[ADDRESS_621438]  number:  [STUDY_ID_REMOVED]  
Date: 23-Apr-2018  
Clinical Trial Protocol  
LP0162 -1341  
Vaccine responses in tralokinumab -treated atopic dermatitis  
ECZTRA 5 (ECZema TRAlokinumab trial no. 5)  
Phase 2  – Vaccine  response trial 
A randomised, do uble-blind, placebo -controlled trial to evaluate t he effect of tralokinumab 
on vaccine antibody responses in adults with moderate -to-severe atopic dermatitis  who are 
candidates for systemic therapy  
This clinical trial will be conducted in compliance with the clinical trial protocol, ICH-GCP 
and the ap plicable regulatory requirements . 
LEO Pharma A/S  Trial ID:  LP0162 -1341  
Date:  23-Apr-[ADDRESS_621439] n o: Not applicable  
Version:   1.0 
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 2 of 123 
Clinical trial protocol statement s 
Approval statement LEO Pharma A/S  
The following persons h ave approved this c linica l trial protocol  by [CONTACT_82032]:  
, MSc Stat  
Biostatistics Lead, Global Clinical Operations  
, MD, PhD  
Medical Lead, Medical Science s and Safety  
, RN, PhD  
Clinical Operations Lead, Global Clinical Operations  
Approval statement signatory investigator  
The signatory investigator approves the clinical trial protocol by [CONTACT_483598], which is a separate document 
appended to this document.  
The following person has approved this clinical trial protocol:  
Joseph F. Merola, MD , MMSc  
Signatory investigator  
Acknowledge ment statement investigator(s)  
Each participating investigator must agree to the approved clinical t rial protocol by [CONTACT_2960] a  
Clinical Trial Protocol Acknowledgement Form  or similar document . 
TMF-000043494 - Version 1. 0
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.[ADDRESS_621440]  ................................ ....................  22 
5.3 Trial rationale  ................................ ................................ ................................ ..............  23 
5.4 Justification for dose  ................................ ................................ ................................ ... 24 
5.5 Ethical considerations  ................................ ................................ ................................ . 24 
5.6 Benefit/risk assessment  ................................ ................................ ...............................  [ADDRESS_621441] eligibility  ................................ ................................ ................................ ........  32 
8.2 Inclusion criteria  ................................ ................................ ................................ .........  32 
8.3 Exclusion criteria  ................................ ................................ ................................ ........  34 
8.4 Screening and screening failures  ................................ ................................ ................  37 
9 Treatments  ................................ ................................ ................................ ..........................  39 
9.1 Description of IMP  ................................ ................................ ................................ ..... 39 
9.1.1  Tralokinumab and placebo  ................................ ................................ ............  39 
9.1.2  Vaccines  ................................ ................................ ................................ .........  40 
9.2 Administration of IMP  ................................ ................................ ................................  41 
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.[ADDRESS_621442] treatment  ................................  44 
9.4 Background treatment (emollients)  ................................ ................................ ............  [ADDRESS_621443] to follow -up ................................ ................................ ................................ ........  55 
11 Trial assessments and procedures  ................................ ................................ ....................  56 
11.1 Overview ................................ ................................ ................................ .....................  56 
11.2 Assessments performed only at screening/baseline  ................................ ....................  57 
11.2.1  Demographics ................................ ................................ ................................  57 
11.2.2  Medical history  ................................ ................................ ..............................  57 
11.2.3  Height and weight  ................................ ................................ .........................  58 
11.2.4  Body surface area involvement  ................................ ................................ ..... 58 
11.2.5  Columbia -Suicide Severity Rating Scale  ................................ ......................  58 
11.3 Efficacy assessments  ................................ ................................ ................................ .. 59 
11.3.1  Investigator ’s Global Assessment  ................................ ................................ . 59 
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.[ADDRESS_621444]  ................................ ................................ . 77 
13.6.2  Overdose ................................ ................................ ................................ ........  79 
13.6.3  Medication error  ................................ ................................ ............................  79 
13.6.4 Misuse  ................................ ................................ ................................ ...........  79 
13.6.5  Abuse  ................................ ................................ ................................ .............  79 
13.6.6  Aggravation of condition  ................................ ................................ ..............  80 
13.7  Follow -up for final outcome of adverse events  ................................ ..........................  80 
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 6 of 123 
13.8  Handling of an urgent safety measure  ................................ ................................ ........  80 
14 Statistical methods  ................................ ................................ ................................ .............  82 
14.1  Sample size  ................................ ................................ ................................ .................  82 
14.2  Trial analysis sets  ................................ ................................ ................................ ........  82 
14.3  Statistical analysis  ................................ ................................ ................................ ....... 84 
14.3.1 Disposition of subjects  ................................ ................................ ..................  84 
14.3.2  Demographics and other baseline characteristics ................................ ..........  84 
14.3.3  Exposure and treatment compliance  ................................ .............................  84 
14.3.4  Multiple testing procedure  ................................ ................................ ............  84 
14.3.5  Analysis of primary endpoints  ................................ ................................ ...... 86 
14.3.6  Analysis of secondary endpoints  ................................ ................................ ... 86 
14.3.7  Analysis of other endpoints  ................................ ................................ ...........  91 
14.3.8  Analysis of safety  ................................ ................................ ..........................  92 
14.3.9  Interim analysis  ................................ ................................ .............................  94 
14.3.10  General principles  ................................ ................................ .........................  94 
14.3.11  Handling of missing values  ................................ ................................ ...........  95 
15 References  ................................ ................................ ................................ ...........................  96 
Appendix 1: Definitions of adverse events and serious adverse events  ...........................  100 
Appendix 2: Classification of adverse events  ................................ ................................ ..... 102 
Appendix 3: Trial governance considera tions  ................................ ................................ ... 105 
Appendix 3A: Regulatory and ethical considerations  ................................ ..............  105 
Appendix 3B: Informed consent process  ................................ ................................ . 106 
Appendix 3C: Subject and data confidentiality  ................................ .......................  106 
Appendix 3D: Record keepi[INVESTIGATOR_007], quality control, and data handling  .........................  107 
Appendix 3E: Registration, reporting and publication policy  ................................ . 112 
Appendix 3F: Insurance  ................................ ................................ ...........................  113 
Appendix 3G: Financial disclosure  ................................ ................................ ..........  113 
Appendix 3H: Trial and site closure  ................................ ................................ ........  114 
Appendix 3I: Responsibilities  ................................ ................................ ..................  115 
Appendix 4: Hanifin and Rajka (1980) diagnostic criteria for AD  ................................ .. 116 
Appendix 5: Guidance for anaphylaxis diagnosis (24)  ................................ .....................  117 
Appendix 6: Short version of eligibility criteria  ................................ ................................  118 
Appendix 7: Contact [CONTACT_4111]  ................................ ................................ ................................ ...... 121 
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 7 of 123 
Appendix 8: WHO model prescribing information for classification of topi[INVESTIGATOR_030]  ................................ ................................ ................................ ..................  [ADDRESS_621445] of panels 
Panel 1: Trial design  ................................ ................................ ................................ .................  16 
Panel 2: Schedule of trial procedures  ................................ ................................ .......................  17 
Panel 3: Objectives and endpoints  ................................ ................................ ...........................  28 
Panel 4: Identification of IMPs (tralokinumab and placebo)  ................................ ...................  39 
Panel 5: Identification of IMPs (vaccines)  ................................ ................................ ...............  40 
Panel 6: Prohibited medication  ................................ ................................ ................................  48 
Panel 7: Sequence of assessments and procedures  ................................ ................................ ... 56 
Panel 8: Investigator ’s Global Assessment  ................................ ................................ ..............  59 
Panel 9: Calculation of the Eczema Area and Severity Index  ................................ ..................  60 
Panel 10: EASI severity score scale and area score scale  ................................ ........................  60 
Panel 11: Clinical laboratory tests  ................................ ................................ ............................  67 
Panel 12: Adverse events of special interest  ................................ ................................ ............  78 
Panel 13: Testing procedure for primary and secondary endpoints  ................................ .........  85 
Panel 14: Transmission of electronic data  ................................ ................................ ..............  111 
Panel 15: Classification of topi[INVESTIGATOR_11930]  ................................ ................................ . 122 
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.[ADDRESS_621446] 50% reduction in EASI score  
EASI75  at least 75% reduction in EASI score  
EASI90  at least 90% reduction in EASI score  
ECG  electrocardiogram  
eCRF  electronic case report form  
ePRO  electronic patient -reported outcome  
EQ-5D-5L EuroQoL 5 -Dimension Health Questionnaire 5 Level  
FAS full analysis set  
FDA  Unites States Food and Drug Administration  
GCP  Good Clinical Practice  
HADS  Hospi[INVESTIGATOR_483572] -related quality of life  
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 9 of 123 
ICF informed consent form  
ICH International Council for Harmonisation  of Technical Requirements for 
Pharmaceuticals for Human Use  
ID identification number  
IGA Investigator ’s Global Assessment  
IgE immunoglobulin E  
IgG immunoglobulin G  
IL interleukin  
IMP investigational medicinal product  
IRB institutional review board  
IRT interactive response technology  
LEO  LEO Pharma A/S  
Lf limit of flocculation  
LOCF  last observation carried forward  
MedDRA  Medical Dictionary for Regulatory Activities  
nAB  neutralising antibodies  
PCR  polymerase chain reaction  
PD pharmacodynamics  
PDE -[ADDRESS_621447] 50% reduction in SCORAD score  
SCORAD75  at least 75% reduction in SCORAD score  
SDTM  study data tabulation model  
SOC  system organ class 
TCI topi[INVESTIGATOR_483573], diphtheria, and acellular pertussis  
Th2 T-helper -2
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.[ADDRESS_621448]  upper limit of normal  
US [LOCATION_002] of America  
UV ultraviolet  
WHO  World Health Organization  
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.[ADDRESS_621449] of 
tralokinumab on vaccine antibody responses in adults with moderate -to-severe 
atopic dermatitis (AD) who are candidates for systemic therapy.  
Short title of trial  Vaccine response s in tralokinumab -treated atopic dermatitis  
Main objectives 
and endpoints  Objectives  Endpoints  
Primary objective  Primary endpoints  
To demonstrate 
non-inferiority of 
tralokinumab versus placebo 
with respect to immune 
responses to concomitantly 
administered vaccines.  Positive ant i-tetanus response at
Week  16 (3 -fold IgG increase compared
to Week  12 if IgG ≤1.0 IU/mL at
Week  12; or IgG ≥2.5  IU/mL if
IgG >1.0 IU/mL at Week  12)
Positive anti-meningococcal response at
Week  16 (IgG ≥3.0  mcg/mL with at
least a 3-fold increase  compared to
Week  12)
Secondary objective  Secondary endpoints  
To evaluate efficacy of 
tralokinumab concomitantly 
administered with vaccines.  Investigator Global Assessment (IGA)
score of 0 (clear) or 1 (almost clear) at
Week  161
At least 75% reduction in Eczema Area
and Severity Index (EASI75) at
Week  162
Additional secondary 
objective  Additional secondary endpoints  
To evaluate safety and 
tolerability of tralokinumab 
concomitantly administered 
with vaccines.  Number of adverse events (AE s)
Presence of anti -drug antibodies
[ADDRESS_621450]'s 
global AD and is based on a 5 -point scale ranging from 0 (clear) to 4 (severe).  
2 The EASI is a validated measure used in clinical practice and clinical trials to assess 
the severity and extent of AD. The EASI is a composite index with scores ranging from 
0 to 72, with higher values indicating more severe and/or more extensive condition.  
Final collection of 
data for the 
primary endpoint s Week 16  
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.[ADDRESS_621451] of a screening  period of 2 to 6 weeks (Weeks  -6/-2 to 0), a 
treatment period of 16 weeks (Weeks 0 to 16) , and a 14 -week off -treatment 
follow -up period for the assessment of safety (Weeks 16 to 30).  Eligible 
subjects may transfer to the open -label , long -term ECZTEND trial 
(LP0162 -1337) at Week 16 or later.  
Subjects will be randomised  in a 1:1 ratio to receive 300 mg (2 mL) of 
tralokinumab or placebo (2  mL) ev ery 2 weeks (Q2W) following a loading 
dose of 600 mg (4 mL ) or placebo (4  mL) on Day  0. Randomisation will be 
stratified by [CONTACT_22789]  (IGA 3 or 4) . 
The last administr ation of IMP will occur at Week  14. Subjects will each 
receive 1  dose of combined tetanus, diphtheria, and acellular pertussis ( Tdap ) 
vaccine and 1  dose of meningococcal vaccine  given intramuscularly at 
Week  12. 
The primary endpoint s will be assessed at Week  16, and the final safety 
assessment will be conducted at Week  30 for those not rolling over to the 
ECZTEND trial (LP0162 -1337) . 
All subjects will use an emollient twice daily (or more, as needed) for at least  
14 days before randomisation and will continue this treatment throughout the  
trial (including safety follow -up). 
Tdap, tetanus, diphtheria, and acellular pertussis; w, weeks.  
Main assessments  Assessment s of vaccine -specific antibody response  
Anti-tetanus response, anti-meningococcal response . 
Safety assessments  
Vital signs, physical examination, electrocardiograms, laboratory testing, 
pharmacokinetics, anti -drug antibodies, and adverse event reporting.  
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 13 of 123 
Efficacy: investigator assessments  
IGA, EASI , and Scoring Atopic Dermatitis ( SCORAD ). 
Efficacy: subject assessments  
4 patient -reported outcomes will be completed by [CONTACT_483599] v isits: Dermatology Life Quality Index (DLQI) , EuroQoL 5 -Dimension 
Health Questionnaire 5  Level (EQ -5D-5L), Patient -Oriented Eczema Measure 
(POEM), and Hospi[INVESTIGATOR_80776] (HADS).  
Main criteria for 
inclusion  Age 18 to 54  years, both included, at screening
Diagnosis of AD as defined by [CONTACT_483600] (1980) criteria for AD
History of AD for ≥1 year
Subjects who have a recent history of inadequate response to treatment
with topi[INVESTIGATOR_421429]
AD involvement of ≥10% body surface area at screening and baseline
according to component A o f SCORAD
An EASI score of ≥12 at screening and 16 at baseline
An IGA score of ≥3 at screening and at baseline
Subjects must have applied a stable dose of emollient twice daily (or more,
as needed) for at least 14 days before randomisation
Main criteria for 
exclusion  Subjects for whom administration of the meningococcal vaccine provided
in this trial is contraindicated or medically inadvisable, according to local
label of the vaccine
Subjects for whom administration of the tetanus, diphtheria, and pertuss is
vaccine provided in this trial is contraindicated or medically inadvisable,
according to local label of the vaccine
Active dermatologic conditions that may confound the diagnosis of AD or
would interfere with assessment of treatment, such as scabies, cutaneous
lymphoma, or psoriasis
Use of tanning beds or phototherapy within  6 weeks prior to randomisation
Treatment with immunosuppressive/ immunomodulating medicat ions
and/or systemic corticosteroids within 4  weeks prior to randomisation
Treatment with th e topi[INVESTIGATOR_483574] (TCS),
topi[INVESTIGATOR_73199] (TCI) or phosphodiesterase 4 (PDE -4)
inhibitor within 2 weeks prior to randomisation
Receipt of any vaccine (except influenza virus vaccines) within 3  months
prior to scree ning, any meningococcal vaccine within 1  year prior to
screening, or any tetanus -, diphtheria -, or pertussis -containing vaccine
within 5  years prior to screening
Receipt of any marketed or investigational biologic agents (e.g.,
cell-depleting agents or dupi[INVESTIGATOR_12458]) within 6  months prior to randomisation
or until lymphocyte  counts return to normal, whichever is longer
History of any active skin infection within 1 week prior to randomisation
History of a clinically significant infection (systemic infection or serious
skin infection requiring parenteral treatment) within 4 weeks prior to
randomisation
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 14 of 123 
Investigational 
medicinal 
products  Tralokinuma b (human recombinan t IL-13 monoclonal antibody)  
150 mg/mL solution for subcutaneous injection in an accessorised pre -filled 
syringe,  1.0 mL fill volume. Each kit contains 1 syringe.  
Placebo  
Placebo solution for  subcutaneous injection in an accessorised pre -filled 
syringe, 1.0 mL fill volume. Each kit contains 1 syringe.  
Tdap  vaccine  
Combined diphtheria, tetanus, acellular pertussis (adsorbed) vaccine. 
Suspension for inje ction in 0.5 mL single dose pre -filled syringes.  
Meningococcal vaccine  
Meni ngococcal (groups A, C, Y and W-135) polysaccharide diphtheria toxoid 
conjugate vaccine. Solution for injection in 0.[ADDRESS_621452]’s trial participation will be up to 36  weeks: screening period  
(including washout, if applicable) up to 6 weeks, treatment period of  16 weeks, 
and follow -up period of 14 weeks  (subjects may enter the long -term extension 
trial, ECZTEND, at any time during the safety follow -up period).  
Number of 
subjects  A total of 200 subjects will be randomised 1:1 to tralokinumab 300  mg Q2W or 
placebo.  
Number and 
distribution of 
trial sites  Approximately 40 sites in the US and Canada.  
Statistical 
methods  Primary endpoints :  
The difference in response rates between treatment groups will be calculated 
using the Mantel -Haenszel estimate of the risk difference stratified by [CONTACT_483601] (IG A 3 or 4) together with the 95%  confidence intervals. 
Non-inferiority of tralokinumab will be demonstrated if the lower limit of the 
95% confidence interval is greater than  -25%.  The per protocol analysis will be 
considered the primary analysis.  Analyses will be based on observed data; thus 
missing data will not be imputed.  
Secondary endpoints :  
The difference in response rates between treatment groups wil l be analysed 
using  the Cochran -Mantel -Haenszel test stratified by [CONTACT_22789] 
(IGA 3 or 4). The primary analysis  will be based on the full analysis set.  
Subjects with missing data or subjects who receive resc ue medication prior to 
Week  16 will be considered as  non-responders in the analysis .  
Testing strategy  
The primary and secondary endpoints will be evaluated hierarchically in the 
order shown in Panel 13. The hypothesis relating to a specific endpoint cannot 
be rejected unless all hypotheses relating to endpoints earlier in the hierarchy 
are also rejected. For the primary endpoints  a non -inferiority hypothesis will be 
tested us ing a non -inferiority limit of -25%.  For the secondary endpoints a 
superiority hypothesis will be tested. All hyp otheses will be tested at a 
one-sided 2.5% significance level. For the primary endpoints, the null 
hypothesis will be rejected if the two -sided 95% confidence interval for the 
difference in immune response rate lies entirely to the right of the 
non-inferiority limit ( -25%). For the secondary endpoints, the hypothese s will 
be tested by [CONTACT_483602] o-sided 95% confidence intervals and p -value . 
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 15 of 123 
Signatory 
investigator  Joseph F. Merola, MD, MMSc  
Brigham and Women’ s Hospi[INVESTIGATOR_307] , [LOCATION_011], MA, [LOCATION_003]  
Sponsor  LEO Pharma A/S, Industriparken 55, DK -2750 Ballerup, Denmark  
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 16 of 123 
2 Trial i dentification  
IND number: 123797  
The clinical trial protocol will be registered in local registries if required by [CONTACT_19666] . 
3 Schematic of t rial design  
Panel 1: Trial design 
Tdap, tetanus , diphtheria, and acellular pertussis;  w, weeks. 
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 17 of 123 
4 Schedule of trial procedures  
Panel 2: Schedule of trial procedures  
Screening  Treatment period  Follow -up2,3 Uns. 
visit6 
(if appl.)  Early 
term.5,7
(if appl.)  Nominal 
Week  16 
visit8 
(if appl.)  References  
(protocol 
section)  Visit  112 3 4 5 6 7 8 9 10 112 124 134 145 11x 
Week  -6 -2 0 2 4 6 8 10 12 14 16 20 24 30 16 
Visit window (days)9 ±3 -3 NA ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 NA NA ±[ADDRESS_621453] eligibility  X X 8.2;8.3 
Treatments and randomisation  
Initiation of emollient 
(background treatment)11 X 9.4 
Concomitant medication X X X X X X X X X X X X X X6 X X 9.6 
Concurrent procedures  X X X X X X X X X X X X X X6 X X 9.6 
Randomisation  X 9.3 
IMP (tralokinumab/placebo) 
administration, compliance  X12 X12 X12 X X X X13 X 9.2.1 ;9.8.4  
IMP ( Tdap  vaccine) 
administration, compliance  X13 9.2.2 ;9.8.4  
IMP (meningococcal vaccine) 
administration, compliance  X13 9.2.2 ;9.8.4  
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 18 of 123 
Panel 2: Schedule of trial procedures (continued)  
Screening  Treatment period  Follow -up2,3 Uns. 
visit6 
(if appl.)  Early 
term.5,7
(if appl.)  Nominal 
Week  16 
visit8 
(if appl.)  References  
(protocol 
section)  Visit  112 3 4 5 6 7 8 9 10 112 124 134 145 11x 
Week  -6 -2 0 2 4 6 8 10 12 14 16 20 24 30 16 
Visit window (days)9 ±3 -3 NA ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 NA NA ±3 
Investigator assessments at screening/baseline only  
C-SSRS X 11.2.5  
Demographics X 11.2.1  
Demographics (a ge)[ADDRESS_621454] assessments of efficacy  
DLQI  X X X X X X X X6 X X [IP_ADDRESS]  
EQ-5D-5L X X X X X X6 X X [IP_ADDRESS]  
POEM  X X X X X X X X6 X X [IP_ADDRESS]  
HADS  X X X X X X6 X X [IP_ADDRESS]  
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 19 of 123 
Panel 2: Schedule of trial procedures (continued)  
Screening  Treatment period  Follow -up2,3 Uns. 
visit6 
(if appl.)  Early 
term.5,7
(if appl.)  Nominal 
Week  16 
visit8 
(if appl.)  References  
(protocol 
section)  Visit  112 3 4 5 6 7 8 9 10 112 124 134 145 11x 
Week  -6 -2 0 2 4 6 8 10 12 14 16 20 24 30 16 
Visit window (days)9 ±3 -3 NA ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 NA NA ±3 
Investigator assessments of safety  
Vital signs  X X12 X12 X12 X X X X X X X X6 X 11.4.1  
Physical examination  X X X X X X6 X 11.4.2  
ECG  X X X X X6 X 11.4.3  
Chemistry, haematology, IgE 
(central laboratory)  X16 X X X X X X X6 X 11.4.[ADDRESS_621455]; hepatitis 
B, C; HIV (central laboratory)  X 11.4.4 ; 
11.4.[ADDRESS_621456]  X X X X X X X6 X 11.4.4  
Urinalysis  X X X X X X X X6 X 11.4.5  
Anti-drug antibodies  X X X X X6 X 11.4.6  
Pharmacokinetics X X X X6 X 11.6 
Adverse events  X X X X X X X X X X X X X X X6 X X 13 
Assessment of vaccine antibody response  
Anti-tetanus response  X X X6,17 X18 X18 11.5 
Anti-meningococcal response  X X X6,17 X18 X18 11.5 
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 20 of 123 
1)For subjects who do not require a wash -out, visits 1 and 2 will be combined and screening will be reduced to 2  weeks; hence, these subjects will only attend
visit 2 (Week  -2) which will include all assessments shown under Week  -6. Similarly, for subjects who only require a 2 -week wash -out, screening visits  1 and 2
will be combined (Week  -2). The screening period has a maximum duration of 6  weeks.
2)Eligible s ubjects may roll over to the ECZ TEND trial at Week  16 or later . See also footnote no. 5.
3)All subjects, except  for those who roll over to the ECZTEND trial (LP0162 -1337), will have a full 14-week off -treatment safety follow -up period . The safety
follow -up period includes 2  telephone conta cts and an office visit (end-of-trial visit) at Week  30. Subjects may transfer to the ECZTEND trial at any time
during the safety follow -up period.
4)Visit will be conducted as a t elephone contact.
5)An end-of-treatment form and end -of-trial form must be  completed in the eCRF for all randomised subjects. See Section  11.10  for further details.
6)Assessments and procedures to be performed at an unscheduled visit are l eft at the investigator’s discretion.
7)Subjects who permanently discontinue IMP or withdraw from the trial will be followed up as described in Section  10.[ADDRESS_621457] dose of IMP .
8)Subjects who permanently discontinue IMP prior to Week  16 wi ll also attend the nominal Week  16 visit (visit 11x) .
9)If the date of a trial visit does not conform to the clinical trial protocol , subsequent visits should be planned to maintain the visit schedule rela tive to baseline.
10)The informed consent form must be signed prior to performing any protocol -related procedures, including but not limited to  screening evaluations and
wash -out of disallowed medications.
11)All subjects must use an emollient twice daily (or more, as needed) for at least [ADDRESS_621458] continue this treatment throughout  the
trial (including safety follow -up).
12)For the first 3 IMP (tralokinumab/placebo) dosing visits, subjects will be monitored after IMP  administration for immediate drug reactions for a minimum of
[ADDRESS_621459] able, whichever is later (Section  9.2.1 ).
13)Since the 2 vaccinations will be given in the upper arms (1  vaccine in each arm), the IMP (tralokinumab/placebo) injections at Week  12 will be given at a
different anatomical site ( that is , anterior thigh or abdomen ).
14)Where it is not allowed to collect the subject’s full date of birth  per local legislation , the subject’s age in years will also be recorded.
15)The total body surface area affected by [CONTACT_483603] A of SCORAD.
16)IgE not measured at screening.
17)Only to be considered  if the unscheduled visit occurs after Week 12 (that is, after administration of the vaccines).
18)Only required if the subject permanently discontinues IMP (tralokinumab/placebo) after Week 12 (that is, after administration of t he vaccines).
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.[ADDRESS_621460]., applicable; C -SSRS, Columbia -Suicide Severity Rating Scale; DLQI, Dermatology Life Quality Index; EASI, Eczema Area and Severity Index; ECG, 
electrocardiogram; EQ -5D-5L, EuroQoL 5 -Dimension Health Questionnaire 5 Level; HADS, Hospi[INVESTIGATOR_5620]; IGA, Investigator’s Global 
Assessment; IgE, immunog lobulin  E; IMP, investigational medicinal product; NA, not applicable; POEM, Patient Oriented Eczema Measure ; SCORAD, Scoring 
Atopic Dermatitis;  Tdap, tetanus, diphtheria, and acellular pertussis ; term., termination; uns., unscheduled.  
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.[ADDRESS_621461] up to 20% of children and up to 
10% of adults. In its severe form, AD is characterised by [CONTACT_483604], i ntractable 
itch, as well as enhanced susceptibility to bacterial, viral , and fungal skin infections ( 1-4). AD 
is associated with a substantial patient burden that typi[INVESTIGATOR_483575] , sleep 
disturbance, and reductions in work productivity ( 5). 
AD is characterised by [CONTACT_483605]2 pathway with increased skin expression of key Th2 
cytokines i ncluding IL-13 (6, 7). The expression of IL -13 is increased in lesiona l skin 
compared to non -lesional skin, and the proportion of CD4+ and CD8+ cells expressing IL -13 
is upregulated in AD patients compared to individuals without AD ( 6, 8).  
IL-13 acts on keratinocytes to release CCL22 and recruit more IL -13 expressing Th2 cells, 
decrease differentiation, and contribute to decr eased barrier function ( 9). IL-[ADDRESS_621462] cell activation status and, once  allergen cross -links 
IgE on the cell surface, drives histamine release and induces itch ( 10, 11). Indeed, itch is a key 
issue in AD, which drives significant mechanical damage to the skin and further facilitates 
allergen and pathogen entry.  
All of these effects together drive and exacerbate the disease phenotype. A review of the 
available preclinical lit erature from mouse and human ex -vivo models suggests IL -13 as a, if 
not the, central mediator of the AD skin phenotype. Indeed, there i s evidence that blocking the 
IL-4 receptor (which is part of the recep tor complex which also  binds IL -13) with the 
monoclonal antibody dupi[INVESTIGATOR_483576] ( 12). 
5.[ADDRESS_621463]  
Tralokinu mab is a human recombinant monoclonal antibody of the IgG4 subclass that  
specifically binds to human IL -13 and blocks interaction with the IL -13 receptors ( 13-15). A 
compi[INVESTIGATOR_483577] ’s Brochure.  
In total, [ADDRESS_621464] been conducted in subjects with 
asthma, ulcerative colit is, idiopathic pulmonary fibrosis, and in healthy subjects. Further 
information on these trials can be found in the current version of the Investigator ’s Brochure . 
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 23 of 123 
In a phase 2b trial (D2213C00001), adults with moderate -to-severe AD on a background of 
mild to moderate TCS, were treated with 3 differe nt regimens of tralokinumab (45  mg Q2W, 
150 mg Q2W, or 300  mg Q2W) or placebo to evaluate the safety and efficac y over a treatment 
period of 12  weeks. The primary endpoints were change from baseline in EASI at W eek 12 
and the percentage of subjects achieving IGA response of 0 (cle ar) or 1 (almost clear) at 
Week  12. Secondary endpoints included change from baseline in EASI and SCORAD scores,  
EASI50, and SCORAD50 . In th e overall intent -to-treat phase  2b population,  an improvement 
in EASI score at W eek 12 w as seen in the tralokinumab 300  mg Q2W group versus placebo. 
26% of s ubjects achieved an IGA of 0 or  1 in the tralokinumab 300  mg Q2W group versus 
12% in the placebo group. The most commonly reported causally relat ed treatment emergent 
adverse event was upper  respi[INVESTIGATOR_1092] (6  [3.9%] subjects in the combined 
tralokinumab group (45  mg, 150  mg, and 300  mg) and 2  [3.9%] subjects in the placebo 
group).  
In total, more than 2, [ADDRESS_621465] been treated with tralokinumab (cut off date : 
18-Aug-2017 ). The safety of all doses studied so far has been with an acceptable benefit -risk
profile and no major safety concerns have been identified. Possible risks associated with use 
of tralokinumab are summarised in Section  5.5. 
5.3 Trial rationale  
Tralokinumab blocks IL -13 signalling and thereby [CONTACT_483606]2 response se en in patients with AD ( 3, 13, 16, 17); refer also to 
Section  5.1. This immunomodulation could potentially impair the immune response and 
compromise immunity in treated patients. Since vaccination prog rammes are an important 
part of health maintenance and globally recommended,  it is relevant to investigate if 
tralokinumab affects development of vaccination -induced immune responses ( 18).  
This trial will assess immunisation responses against 2 vaccines ( a combined tetanus , 
diphtheria, and acellular pertussis  [hereinafter ‘Tdap ’] vaccine and a meningococcal  [groups 
A, C, Y and W -135] polysaccharide  conjugated  vaccine ) in adults with moderate -to-severe 
AD who are treated with tralokinumab . These [ADDRESS_621466] of tralokinumab on immune activation. The selected 
types of vaccines are known to result in an immune response involving both T and B cells as 
well as other key c ell types of the immune system.  
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 24 of 123 
5.4 Justification for dose  
The selected dose for this trial is 300  mg tralokinumab administered subcutaneously Q2W. All 
subjects randomised to receive treatment with tralokinumab will get an initial loading dose o f 
600 mg on Day  0 (baseline). The administration of the loading dose of tralokinumab will 
allow systemic concentrations to reach steady -state faster, and potentially reduce the time to 
onset of clinical effect. The serum concentration s of tralokinumab after the 600  mg loading 
dose will not exceed the serum tralokinumab concentrati ons at steady state for the 300  mg 
Q2W.  
The tralokinumab 300 mg Q2W dose was chosen based on the results of th e phase 2b trial in 
subjects with moderate -to-severe AD (trial D2213C00001) described in Section  5.2. The 
subjects were treated with 3 different fixed dose regimens  of tralokinumab (45, 150, or 
300 mg Q2W) or placebo to evaluate safety and efficacy over a treatment period of 12  weeks. 
In the overall intention -to-treat phase 2b population, a statistically significant improvement in 
EASI change from baseline at Week 12  was o bserved in the tralokinumab 300  mg group 
versus placebo; however, formal statistical significance was not demonstrated for the 
co-primary endpoint IGA. The key secondary and exploratory endpoint results from 
trial D2213C00001 also support the select ion of the tralokinumab Q2W 300  mg dose; and 
overall, larger numerical differences were observed for [ADDRESS_621467] of the trial endpoints.  
Since the safety profile in trial D2213C00001 was acceptable i n all treatment cohorts and no  
clear safety related dose -response pattern was identified, the dose of 300 mg Q2W has been 
selected for evaluation in this trial.  
The 300  mg Q2W dose is also used in the  ongoing phase 3 trials ECZTRA  1, ECZTRA  2, and 
ECZTRA  3. 
The Tdap  and the meningococcal vaccines  will be given according to the local labelling, that 
is, a single intramuscular injection (0.5  mL) of each  vaccine . 
5.[ADDRESS_621468] to agree to use a highly effective  method of contraception to prevent pregnancy during 
the clinical trial and until 16  weeks after discontinuation of treatment with the IMP. In 
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.[ADDRESS_621469] performed 
before, during and at end-of-treatment to ensure that no foetuses are exposed to the IMP.  
In a 13 -week repeated -dose nonclinical study in male cynomolgus monkeys, no adverse 
effects on male reproductive endpoints were observed ( see the Investigator ’s Brochure). 
Coupled with the negligible exposure risk for drugs and antibodies by [CONTACT_483607] a pregnant woman or in the conceptus ( 19), it is 
not considered necessary to impose restrictions on fathering a child or sperm donation in 
clinical trials with tralokinumab.  
In this clinical trial in adult subjects with moderate -to-severe AD who are otherwise health y, 
the immunisation responses again st [ADDRESS_621470] ’s AD is carefully monitored and treated as needed in this trial. Rescue 
treatment may be given to the subjects at the investigator ’s discretion f or the duration of the 
trial. If subjects receive rescue treatment with systemic corticosteroids or non -steroidal 
systemic immunosuppressive drugs, treatment with IMP will be immediately discontinued.  
Investigators should only enrol subjects  they expect wi ll be able to complete the wash -out of 
previous AD medications without experiencing intolerable worsening of their AD. Subjects 
will be informed to contact [CONTACT_483608] a significant worsening of th eir 
AD.   
Altogether, the risks associated with participating in this clinical trial are considered ve ry low 
and outweighed by [CONTACT_73292] a potential future treatment option for moderate -to-severe 
AD.  
In accordance with the current version of the ICH GCP  guidel ines, qualified medical 
personnel employed by [CONTACT_483609] -related medical 
questions. Medical monitoring will be performed throughout the trial  and s afety data will be  
reviewed regularly by [CONTACT_483610] L EO to ensure that prompt action is taken, 
if needed, to maximise patient safety.  
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 26 of 123 
In conclusion, the trial design chosen for this vaccine response trial with tralokinumab is 
regarded as ethically justified and adherent with ethical requirements.  
5.6 Benefit/ risk assessment  
There is an unmet medical need for new therapi[INVESTIGATOR_421410] -to-severe 
AD as current immunosuppressive medications, such as cyclosporine, methotrexate, and 
azathioprine, have associated long -term toxicities.  
Tralokinuma b has already demonstrated efficacy in moderate -to-severe AD , and has shown an 
acceptable safety profile in AD, asthma, ulcerative colitis, idiopathic pulmonary fibrosis, and 
in trials with healthy subjects. The evidence discussed in Section  5.[ADDRESS_621471] been identified that are described in the current version of the 
Investigator’s Brochure, including hypersensitivity reactions, immune comple x disease, 
severe infections, malignancies, and interference with reproductive function; measures are in 
place in this trial to protect participating subjects as follows:  
Close monitoring of subjects during the trial with trial visits every 2 weeks
during the treatment period (see the schedule of trial procedures in Section  4).
Close monitoring of subjects during the post -dosing period (at the first 3 IMP
dosing visits) as a precautionary measure against hypersensitivity reactions
(further details are given in Section  9.2).
Monitoring of subjects for clinical manifestations that may be associated with
the development of specific antibodies to tralokinumab (i.e., immune complex
disease).
Exclusion of subjects with untreated systemic helminth infestations or subjects
who have failed to respond to standard of care  therapy . Neutralisation of IL -13
might theoretically cause a worsening of parasitic infestation, in particular,
prevention of expulsion of gastrointestinal worms (helminths) (20).
Exclusion of subjects with a history of tuberculosis requiring treatment within
12 months prior to the screening visit.
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 27 of 123 
Exclusion of subjects with a history of a clinically significant infection
(defined as a systemic or serious skin infection requiring parenteral antibiotics,
antiviral, or anti -fungal medication; see Section  8.3) within 4 weeks prior to
baseline which, in the opi[INVESTIGATOR_26335] ’s medical expert,
may compromise the safety of the subject in the trial.
In conclusion, previous clinica l experience with tralokinumab shows no major safety or 
tolerability concerns and appropriate measures have been instituted in this trial to protect 
subjects from possible risks that have been previously identified and to closely monitor each 
subject. The current risk/benefit ratio is favourable and supports the administration of 
tralokinumab in combination with the 2  vaccines for the purposes of achieving the objectives 
of this trial.  
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 28 of 123 
6 Trial  objectives  and endpoints  
Panel 3: Objectives and endpoints  
Objectives  Endpoints  
Primary objective  Primary endpoints  
To demonstrate non-inferiority of 
tralokinumab versus placebo with 
respect to immune responses to 
concomitantly administered 
vaccines.  Positive anti -tetanus resp onse at Week  16 (3-fold IgG
increase compared to Week  12 if IgG ≤1.0 IU/mL a t
Week  12; or IgG ≥2.5 IU/mL if IgG >1.0 IU/mL at
Week  12)
Positive anti-meningococcal response at Week  16
(IgG ≥3.0 mcg/mL with at least a 3-fold increase
compared to Week  12)
Secondary objective  Secondary endpoints  
To evaluate efficacy of 
tralokinumab concomitantly 
administered with vaccines.  IGA score of 0 (clear) or 1 (almost clear) at Week  16
EASI75 at Week  16
Additional secondary objective  Additional secondary endpoints  
To evaluate safety and tolerability 
of tralokinumab concomitantly 
administered with vaccines.  Number of AEs
Presence of anti -drug antibodies
Other objectives  Other endpoints  
To evaluate the efficacy of  
tralokinumab concomitan tly 
administered with vaccines on 
severity and extent of  AD and 
health -related quality of  life. EASI50 at Week  16
EASI90 at Week  16
Change from baseline to Week  16 in EASI score
SCORAD75 at Week  16
SCORAD50 at Week  16
Change from baseline to Week 16 in SCORAD
Change from baseline to Week  16 in DLQI score
Change from baseline to Week  16 in EQ -5D-5L
Change from baseline to Week  16 in POEM
Change from baseline to Week  16 in HADS
AE, adverse event; DLQI, Dermatology Life Quality Index; EASI, Eczema Area and Severity Index; EASI50, at 
least 50% reduction in EASI score; EASI75, at least 75% reduction in EASI score; EASI90, at least 90% 
reduction in EASI score; EQ -5D-5L, EuroQoL 5 -Dimension Health Questionnaire 5 Level; HADS, Hospi[INVESTIGATOR_70505]; IGA, Investigator’s Global Assessment; POEM, Patient -Oriented Eczema 
Measure; SAE, serious adverse event; SCORAD, Scoring Atopic Dermatitis; SCORAD50, at least 50% 
reduction in SCORAD score; SCORAD75, at leas t 75% reduction in SCORAD score . 
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.[ADDRESS_621472] of a screening period of 2 to 6  weeks (Weeks  -6/-2 to 0), a treatment 
period of 16 weeks (Weeks  0 to 16) and a 14 -week off -treatment follo w-up period for the 
assessment of safety (Weeks  16 to 3 0). The primary endpoint s will be assessed at Week 16, 
and the final safety assessment will be conducted at Week  30 (end-of-trial visit) . Eligible 
subjects may transfer to the open -label ECZTEND trial (LP0162 -1337) at Week  16 or later . 
An overview of the different parts of the trial is provided in Panel 1. 
Screening period (Week -6 to Week 0)  
The scr eening period has a minimum duration of [ADDRESS_621473] duration of the screening period 
depends on the washout period defined by [CONTACT_121566] (Section  8.3). If a washout is 
not required, screening will be reduced to 2  weeks and only requires 1  visit (Week  -2; visit  2), 
i.e., the 2  screening visits will be merged. Similarly, if only a 2-week wash -out is required,
screening visits 1 and 2 will be combined (Week  -2; visit  2). All subjects will attend a 
screening visit 14  days before baseline (Week  -2; visit  2). Eligibility will be assessed at the 
(first) screening visit and on Day  0 prior to randomisation.  
All subjects will use an emollient twice daily (or more, as needed) for at least 14 days befor e 
randomisation and will continue this treatment throughout the trial  (including safety 
follow -up). Subjects will initiate emollient treatmen t no later than the Week  -2 visit.  
Treatment period (Week 0 to Week 16)  
Following the screening period, approximately 200 subjects will be randomis ed 1:1 to one of 
the following groups stratified by [CONTACT_89309] (IGA of 3 or 4) : 
Tralokinumab 600 mg (4  mL) at Day  0 (hereinafter “baseline ”), then 300 mg
(2 mL) Q2W.
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 30 of 123 
Placebo (4  mL) at baseline, then placebo (2  mL) Q2W.
Subjects will each receive [ADDRESS_621474] administration of IMP will occur at Week  14. 
Safety follow -up period (Week 16 to Week 30)  
All subjects, except for those who transfer to the ECZTEND trial (LP0162 -1337), will 
complete a full 14-week off -treatment follow -up period  which includes 2  telephone  contacts  
and an office visit at Week 30 for assessment of safety , PK,  and ADA.  
Long -term extension trial  
Eligible subjects may be invited to enter an open -label, long -term extension trial conducted 
under a separate protocol (LP0162 -1337, ECZTEND). Subjects who fulfil the eligibility 
criteria in the ECZTEND protocol can enter the trial at the Week  [ADDRESS_621475] 
had their Week  16 visit under the current protocol (LP0162 -1341).  
7.2 Number of subjects needed  
Assuming a screening failure rate of 25%, approximately 267  subjects will be  screened and 
approximately 200  subjects will be randomly assigned to trial treatment. The statistical power 
consideration s for this sample size (n=200) are described in Section  14.1. 
This trial will be conducted at approximately  [ADDRESS_621476] completed all periods of the 
trial i ncluding the safety follow -up visit (Week  30) or if they have transferred to the 
ECZTEND trial (Section  7.1). 
The end of the trial is defined as the date of the last visit of the last subject in the tri al 
globally.  
Final collection of data for the primary endpoint s will occur  at Week  16. 
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 31 of 123 
7.4 Software  
CDISC controlled terminology version 22-Dec-2017 was used for definition of controlled 
terminology used  throughout this protocol and will be used for  statistical programming and 
output.  SDTM version 1.4 and SDTM implementation guide version  3.2 will be used for data 
tabulations . 
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.[ADDRESS_621477] ’s eligibi lity for the clinical trial must  be verified according to the inclusion and 
exclusion criteria at visits specified in Panel 2. It will be recor ded in the eCRF if the subject 
has met all the inclusion criteria and none of the exclusion criteria.  
Any implementation of national requirements/law for the subject ’s participation in the clini cal 
trial will be ensured and described in submission document ation to regu latory authorities and  
IRBs , as applicable.   
8.[ADDRESS_621478] fulfil all of the following criteria : 
1.Written informed consent and any locally required authorisation obtained from the
subject prior to performing any protocol -related procedures, including screening
evaluations.
2.Age 18 to 54  years, both included , at screening .
3.Diagnosis  of AD as defined by [CONTACT_85811] (1980) criteria for AD ( 21;
Appendix 4 ).
4.History  of AD for ≥[ADDRESS_621479] a recent history (within 1  year before the screening visit) of
inadequate response to treatment with topi[INVESTIGATOR_421411] (e.g., due to important side effects or
safety risks).
Inadequate response is defined as failure to achieve and maintain remission or
a low disease activity state (comparable to IGA 0=clear  to 2=mild) despi[INVESTIGATOR_421412] a daily regimen of TCS of medium to higher potency (±TCI as
appropriate), applied for at least [ADDRESS_621480] prescribing information (e.g., 14  days for
super -potent TCS), w hichever is shorter.
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 33 of 123 
Subjects with documented systemic treatment for AD in the past year are also
considered as inadequate responders to topi[INVESTIGATOR_483578].
Important si de effects or safety risks are those that outweigh the potential
treatment benefits and include intolerance to treatment, hypersensitivity
reactions, significant skin atrophy, and systemic effects, as assessed by [CONTACT_421448] ’s treati ng physician.
6.AD involvement of ≥10% body surface area at screening and baseline (visit  3)
according to component A of SCORAD .
7.An EASI score of ≥12 at screening and 16 at baseline.
8.An IGA score of ≥[ADDRESS_621481] applied a stable dose of emollient twice daily (or more, as needed )
for at least [ADDRESS_621482] use a highly effective* form of birth control
(confirmed by [CONTACT_093]) throughout the trial and at le ast for 16  weeks
(5 half-lives) after last administration of IMP.
*A highly effective method of birth control is defined as one which results in a low
failure rate (less than 1% per year) such as bilateral tubal occlusion, intrauterine 
device (IUD), intrau terine hormone -releasing system (IUS), combined (oestrogen and 
progestogen containing) hormonal contraception associated with inhibition of 
ovulation (oral, intravaginal, transdermal), progestogen -only hormonal contraception 
associated with inhibition of o vulation (oral, injectable, implantable), sexual 
abstinence (when this is in line with the preferred and usual life style of the subject), 
vasectomised partner (given that the subject is monogamous). The subjects must have 
used the contraceptive method con tinuously for at least [ADDRESS_621483] at baseline. A female is defined as not being of child -bearing potential if she is 
postmenopausal (at least 12  months with no menses without an alternative medical 
cause prior to screening), or sur gically sterile (hysterectomy, bilateral salpi[INVESTIGATOR_421414]).  
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.[ADDRESS_621484] not enter the trial if any of the following exclusion criteria are fulfilled:  
1.Concurrent enrolment in another clinical trial where the subject is receiving an IMP.
2.Previous randomisation in tralokinumab trials.
3.Subjects for whom administration of the meningococcal vaccine provided in this trial
is contraindicated or medically inadvisable, according to local label of the vaccine.
4.Subjects for whom administration of the tetanus, diphtheria, and pertussis vaccine
provided in this trial is contraindicated or medically inadvisable, according to local
label of the vaccine.
5.Active dermatologic conditions that may confound  the diagnosis of AD or would
interfere with assessment of treatment, such as scabies, cutaneous lymphoma, or
psoriasis.
6.Known active allergic or irritant contact [CONTACT_483611].
7.Use of tanning beds or phototherapy (narrow band ultraviolet B [NBUVB],
ultraviolet  B [UVB], ultraviolet A1 [UV A1], psoralen + ultraviolet A [PUVA]), within
6 weeks prior to randomisation.
8.Treatment with the following medications within 4 weeks prior to randomisation:
Systemic immunosuppressive/immunomodulating drugs (e.g. methotrexate,
cyclosporine, azathioprine, mycophenolate mofetil, Janus kinase inhibitors
etc.).
Systemic corticosteroid use (excludes topi[INVESTIGATOR_2855], inhaled, or intranasal delivery)
Three or more bleach baths  during any week within the 4  weeks.
9.Treatment with the following medications within 2  weeks prior to randomisation
TCS.
TCI.
Topi[INVESTIGATOR_22732] -4 inhibitor.
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 35 of 123 
10.Receipt of any vaccine  (except influenza virus vaccines) within [ADDRESS_621485] -reported.
11.Receipt of any marketed (i.e. immunoglobulin, anti -IgE) or investigational biologic
agent, including dupi[INVESTIGATOR_12458]:
Any cell -depleting agents including but not limited to rituximab: within
6 months prior to randomisation, or until lymphocyte count returns to normal,
whichever is longer.
Other biologics: within 3  month s or 5  half-lives, whichever is longer, prior to
randomisation.
12.Receipt of any investigational non -biologic agent within 5  half-lives prior to
randomisation.
13.Receipt of blood products within 4  weeks prior to screening.
14.Major surgery within 8  weeks pr ior to screening, or planned in -patient surgery or
hospi[INVESTIGATOR_421415].
15.Known or suspected allergy or reaction to any component of the IMP formulatio ns.
16.History of any  active skin infection within 1  week prior to randomisation.
17.History of a  clinically significant infection within 4  weeks prior to randomisation
which, in the opi[INVESTIGATOR_26335] ’s medical expert, may compromise
the safety of the subject in the trial, interfere with evaluation of the IMP, or reduce the
subjec t’s ability to participate in the trial. Clinically significant infections are defined
as:
a systemic infection.
a serious skin infection requiring parenteral (intravenous or intramuscular)
antibiotics, antiviral, or antifungal medication.
18.A helmin th par asitic infection within [ADDRESS_621486] of care
therapy.
19.History of anaphylaxis following any biologic therapy.
20.History of immune complex disease.
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 36 of 123 
21.History of cancer:
Subjects who have had basal cell carcinoma, localised squamous cell
carcinoma of the skin or in situ carcinoma of the cervix are eligible provided
that the subject is in remission and curative therapy  was completed at least
12 months prior to the date informed consent was obtained.
Subjects who have had other malignancies are eligible provided that the
subject is in remission and curative t herapy was completed at least [ADDRESS_621487] of care.
23.History of any known primary immunodeficiency disorder including a positive h uman
immunodeficiency virus (HIV) test at screening, or the subject taking antiretroviral
medications as determined by [CONTACT_70266]/or subject ’s verbal report.
24.History of chronic alcohol or drug abuse within 12  months prior to screening, or any
cond ition associated with poor compliance as judged by [CONTACT_093].
25.History of attempted suicide or is at significant risk of suicide (either in the opi[INVESTIGATOR_421416] a “yes” to suicidal ideation questions no.  4 or 5 or
answering “yes” to suicidal behaviour on the Columbia -Suicide Severity Rating Scale
[C-SSRS] Screening version).
26.Any disorder, including but not limited to, cardiovascular, gastrointestinal, hepatic,
renal, neurological, musculoskeletal, infectious, endocrine, metabo lic, haematological,
immunological, psychiatric, or major physical impairment that is not stable, in the
opi[INVESTIGATOR_871], and could:
Affect the safety of the subject throughout the trial.
Influence the findings of the trial or their interpretat ions.
Impede the subject ’s ability to complete the entire duration of trial.
27.Any clinically significant abnormal findings in physical examination, vital signs,
electrocardiogram (ECG), haematology, clinical chemistry, or urinalysis during the
screening per iod, which in the opi[INVESTIGATOR_871], may put the subject at risk
because of his/her participation in the trial, or may influence the results of the trial, or
the subject ’s ability to complete entire duration of the trial.
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 37 of 123 
28.Alanine aminotransferase  (ALT) or aspartate aminotransferase (AST) level ≥2.[ADDRESS_621488] (upper limit of normal) at screening.
29.Positive hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (HBsAb),
hepatitis B core antibody (HBcAb) or hepatitis C virus antibody ( anti-HCV) serology
at screening. Subjects with positive HBsAb may be randomised provided they are
hepatitis B vaccinated and have negative HBsAg and HBcAb.
30.Subjects who are not willing to abstain from donating blood and/or plasma from the
time of informed consent and for 16  weeks (5  half-lives) after last dose of IMP.
31.Subjects who are legally institutionalised.
32.Pregnant, breastfeeding, or lactating women.
33.Employees of the trial site or any other individuals directly involved with the planni ng
or conduct of the trial, or immediate family members of such individuals .
8.[ADDRESS_621489] been assigned a subjec t ID are 
considered ‘screened ’ subjects.   
The investigator will maintain a log of all consented subjects at the trial site  (‘subject 
identification list’). This log  will include each subject ’s identity, date of consent and 
corresponding subject ID so that any subject may be identified if required for any reason. T he 
log must not be copi[INVESTIGATOR_121482].  In addition, the investigator will maintain a log of 
all subjects considered for screening, whether they have prov ided written informed consent  or 
not (‘screening log ’). This log will be anonymous and will include the reason(s) for not 
entering the trial, if applicable, or the allocated subject ID.  
Screening failures  
Screen ing failures are defined as subjects who cons ent to participate in the trial but are not 
subsequently randomly assigned to trial treatment. A minimal set of screen ing failure 
information is required to ensure transparent reporting of screen ing failure subjects to meet 
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 38 of 123 
the Consolidated Standards of Re porting Trials (C ONSORT) publishing requirements  (22) 
and to respond to queries from regulatory authorities.  
The following data will be collected in the eCRF for screening failures:  
Date of informed consent .
Demographics (date of birth, sex, e thnicity, race) .
Reason for screen  failure:
Failure to meet eligibility  criteria .
Lost to follow -up.
Withdrawal by [CONTACT_1130] .
Other.
Date of screen failure .
Any AEs and SAEs .
In case of any SAEs, these must be followed -up as described in Section  13.7. 
Individuals who do not meet the criteria for participation in this trial (screening failures) may 
not be re -screened. However, if the reason for screening failure is administrative and not due 
to the subject failing to me et the eligibility criteria, re -screening may be permitted (this will 
require approval by [CONTACT_456] ’s medical expert [INVESTIGATOR_483652]. Individuals who are re -screened will get a new 
subject ID. 
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 39 of 123 
9 Treatments  
9.1 Description  of IMP  
9.1.1 Tralokinumab and placebo  
Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that 
specifically binds to human IL -13 and blocks interaction with the IL -13 receptors. It is 
presented as a liquid formulation for S C administration.  
Tralokinumab and placebo will be packaged in individually numbered kits, each containing 
1 syringe. Refer to Panel 4 for further details.  
Panel 4: Identification of IMP s (tralokinumab and placebo)  
Investigational 
medicinal 
product  Dosage form  and 
pack size  Active ingredient and concentration Source  
Tralokinumab  150 mg/mL solution 
for injection in an 
accessorised 
pre-filled syringe, 
1.0 mL fill volume.  Formulated at a nominal concentration 
of 150  mg/mL in 50mM sodium 
acetate/acetic acid buffer, 85mM 
sodium chloride, 0.01% (w/v) PS -80, 
pH 5.5 solution.  MedImmune  
Placebo  Placebo solution for 
injection in an 
accessorised 
pre-filled syringe, 
1.0 mL fill volume.  Placebo contains the same excipi[INVESTIGATOR_840], 
in the same concentration only lacking 
tralokinumab  MedImmune  
The accessorised prefilled syringe is a single use, disposable system that is designed to 
administer the labelled dose of the system to the subcutaneous space during 1  injection and 
automatically provide a safety mechanism to reduce the occurrence of accid ental needle stick s 
during disposal of the system.  
The accessorised prefilled syringe consists of a pr efilled syringe sub -assembly (1  mL pref illed 
syringe barrel with a 1/2  inch 27  gauge thin wall staked in needle, rigid needle shield, plunger 
stopper) and a safety device.  
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 40 of 123 
9.1.2 Vaccines  
The Tdap and menigococcal vaccines will be packaged in individually numbered kits, each 
containing 1 vial or 1  pre-filled syringe.  Refer to  Panel 5 for further details  
Panel 5: Identification of IMPs (vaccines)  
Investigational 
medicinal 
product  Dosage form  and 
pack size  Active ingredient and concentration  Source  
Tdap  vaccine  Suspension for 
injection in 0.5  mL 
single -dose 
pre-filled syringes.  Combined diphtheria, tetanus, acellular 
pertussis (adsorbed) vaccine.  
The vaccine contains diphtheria toxoid, 
tetanus toxoid, and 3  purified pertussis 
antigens (pertussis toxoid, filamentous 
haemagglutinin, and pertactin) adsorbe d 
onto aluminum salts. The final vaccine is 
formulated in saline.  
Each 0.5  mL dose is formulated to 
contain 5  limit of flocculation (Lf) of 
tetanus toxoid, 2.5 Lf of diphtheria 
toxoid, 8 mcg of inactivated pertussis 
toxoid, 8 mcg of filamentous 
haemaggluti nin, and 2.5  mcg of pertactin 
(69 kDa outer membrane protein).  Commercially 
available ; 
supplied by 
[CONTACT_483612] . 
Meningococcal 
vaccine  Solution for 
injection in 0.5  mL 
single -dose vials.  Meningococcal (groups A, C, Y and 
W-135) polysaccharide diphtheria toxoid  
conjugate vaccine.  
Each 0.5 mL dose of vaccine is 
formulated in sodium phosphate 
buffered isotonic sodium chloride 
solution to contain 4 mcg each of 
meningococcal A, C, Y and W -135 
polysaccharides  conjugated to 
approximately 48  mcg of diphtheria 
toxoid pr otein carrier.  Commercially 
available; 
supplied by 
[CONTACT_483612] . 
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 41 of 123 
9.2 Administration of IMP  
9.2.1 Administration of tralokinumab and placebo  
Dosing visits are shown in the schedule of trial procedures (Section  4). The last administration 
of IMP (tralokinumab/placebo) will occur at Week  14. 
The first day of dosing is considered Day 0 (visit 3). Each subject will receive 4  SC injection s 
(each 1.0  mL) o f 150 mg tralokinumab or placebo to receive a total loading dose of 
600 mg tralokinumab or placebo ( 4.0 mL) . 
At subsequent visits (Q2W) in the treatment period, each subject will receive 2  SC injection s 
(each 1.0  mL) of 150  mg tralokinumab or placebo to receive a total dose of 300  mg 
tralokinumab or placebo  (2.0 mL).  
The IRT will assign the required kit numbers for each subject at each dispensing visit.  
IMP (tralokinumab/placebo) will be administered by a qualified, unblinded HCP ( refer to  
Section  9.3.1  for blinding details). A  minimum interval of [ADDRESS_621490] been 
completed (Section  11.1). 
The injections will be administered into the SC tissue of the upper arm, anterior thigh, or 
abdomen, separated by [CONTACT_2669] [ADDRESS_621491] be recorded in the source 
documents at each treatment visit and recorded in the eCRF.  
Although the sug gested anatomical site for the tralokinumab/placebo injections at Week  12 is 
the right upper arm  (refer to the injection rotation scheme described in the IMP manual) , it 
should be noted that in this trial, the tralokinumab/placebo injections at Week  12 wil l be 
administered in one of the other allowed anatomical sites ( anterior thigh or abdomen ). This is 
due to the fact that the [ADDRESS_621492] be injected intramuscularly 
in the deltoid area (Section  9.2.2 ). 
Further details on IMP administration are provided in a n IMP manual . IMP administration 
must be carried out according to these instructions.   
After IMP administration  
For the first 3 IMP dosing visits ( Day 0, Week  2, and Week  4), subjects will be monitored 
after IMP administration for immediate drug reactions for a minimum of 30 minutes with vital 
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 42 of 123 
signs taken at 30 minutes or until stable, whichever is later. Vital signs will be documented  in 
the eCRF.  
As with any antibody, allergic reactions to dose administration are possible. The World 
Allergy Organization has categorised anaphylaxis into 2  subgroups: allergic anaphylaxis 
(mediated by [CONTACT_421450]) and nonallergic anaphylaxis  (which has a 
nonimmunologic cause) ( 23). The clinical criteria for defining anaphylaxis for this trial are 
listed in  Appendix 5  (24). Appropriate drugs, such as epi[INVESTIGATOR_238], antihistamines, 
corticosteroids, etc., and medical equipment to treat a cute anaphylactic reactions must be 
immediately available at trial sites, and trial personnel should be trained to recognise and 
respond to anaphylaxis according to local guidelines.  
If an anaphylactic reaction occurs, a blood sample will be drawn from the  subject as soon as  
possible after the event, at 60  minutes ± 30  minutes after the event, and at discharge for 
analysis of serum tryptase at the central laboratory.  
Conditions requiring IMP administration rescheduling  
If any of the following should occur, the investigator should reschedule the visit and IMP 
should not be administered until the rescheduled visit:  
The subject has an intercurrent illness, that in the opi[INVESTIGATOR_421417] (e.g., viral  illnesses).
The subject is febrile (defined as ≥38°C; ≥100.4 °F) within 72  hours prior to
IMP administration.
If the trial visit cannot be rescheduled in  order to maintain minimum of 7  days to subsequen t 
dose, the sponsor ’s medical expert [INVESTIGATOR_73371][INVESTIGATOR_530].  
9.2.2 Administration of vaccines  
At visit 9 (Week  12), subjects will each receive 1  dose of  Tdap  and meningococcal vaccines 
(refer to the schedule of trial procedures [Section  4]). The vaccines will be administered by 
[CONTACT_483613]/placebo injections are administered ; the vaccines 
will be given first, then tralokinumab/placebo will be given (see below) . 
The [ADDRESS_621493] be recorded in the source documents and 
recorded in the eCRF.  
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.[ADDRESS_621494] will be kept under observation for 30 minutes following vaccination. Aft er this 
observational period, the 2  tralokinumab/placebo injections will be given ( Panel 7). Note that 
at Week  12, the tralokinumab/placebo injections will be given i n the anterior thigh or 
abdomen.  
Appropriate drugs, such as epi[INVESTIGATOR_238], antihistamines, corticosteroids, etc., and medical 
equipment to treat acute anaphylactic reactions must be immediately available at trial sites , 
and trial personnel should be trained to recognise and respond to anaphylaxis according to 
local guidelines.  
Syncope can occur in association with administration of the vaccines. Procedures should be i n 
place to prevent falling injury and to restore cerebral perfusion following syncope.  
For each vaccine, the IRT will assign the required kit number for each subject.  
Conditions requiring vaccine administration rescheduling  
If any of the following should occur, the investigator should reschedule the visit and IMP 
(vaccines) should not be adminis tered until the rescheduled visit:  
The subject has an intercurrent illness, that in the opi[INVESTIGATOR_421417] (e.g., viral illnesses).
The subject is febrile (defined as ≥38°C; ≥100.4 °F) within 72 hours prior to
IMP administration.
If the trial visit cannot be rescheduled in order to maintain minimum of 7  days to subsequen t 
dose, the sponsor ’s medical expert [INVESTIGATOR_73371][INVESTIGATOR_530].  
9.[ADDRESS_621495] been found to comply with al l the inclusion criteria and not to violate an y 
of the exclusion criteria will be randomised at baseline (Day 0) to receive treatment with 
either tralokinumab or placebo. Treatment assignment will be pre -planned according to a 
computer generated randomisat ion schedule in a 1:1 ratio (tralokinumab:placebo) stratified by  
[CONTACT_22789] (IGA 3 or 4).  
IRT will be used to control randomisation and stratification factors, along with IMP supply 
chain and expi[INVESTIGATOR_73226].  
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341 Date: 23-Apr-2018  Version: 1.[ADDRESS_621496] and not matched for viscosity, IMP 
(tralokinumab/placebo) will be handled and administered by a quali fied, unblinded HCP at the 
site who will not be involved in the management of trial subjects and who will not perform 
any of the assessments.  
In the event that the treatment allocation for a subject becomes known to the investigator o r 
other study staff in volved in the management of trial subjects, LEO must be notified 
immediately.  
Should an issue arise with the IMP (e.g., damaged kit or syringe that has been assigned to a  
subject prior to administration, or any other unexpected event with the kit or syrin ge [e.g.,  a 
malfunction during IMP administration]), the unblinded HCP at the site will contact [CONTACT_483614].  
The trial site will maintain a written plan detailing which staff members are blinded/unblin ded 
and the process of IMP administration used to maintain the blind.  
Analysis of data per last subject ’s Week 16 visit  
To support submission for marketing approval, an analysis of trial data up to and including 
visit 11 (Week  16) will be performed and will require unblinding of data. To perform this 
analysis, an analysis group consisting of a Medical Expert, a Statistician, a Statistical 
Programmer and a Medical Writer will be unblinded to individual subject treatment allocation  
following database lock for t he [ADDRESS_621497] ’s safety. An emergency unblinding request can be 
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.[ADDRESS_621498] ’s treatment in the 
IRT. For a requester who is not a member of the trial staff and who does not have access to the 
IRT (e.g., a physician at an emergency room ), a local contact [CONTACT_73298] (see Appendix 3B) to be used if the 
investigator or delegated site staff cannot be reached . The req uester will provide the trial ID 
and subject  ID to the emergency unblinding CRO who will immediately reveal the individual 
treatment allocation.  
The emergency unblinding CRO will clarify that the requester requires immediate unblinding 
without further medi cal consultation. Should the requester wish to discuss whether unblindin g 
is necessary, the  emergency  unblinding CRO will divert the requester to the medical cover.  
9.4 Background treatment  (emollients)  
All subjects must use an additive -free, basic bland emollient twice daily (or more, as needed ) 
for at least [ADDRESS_621499] continue their background emollient  
treatment throughout the trial  (including safety follow -up). 
9.5 Rescue treatment  
If medically necessary (i.e., to control i ntolerable AD symptoms), rescue treatment for AD 
may be provided to trial subjects at the discretion of the investigator.  
If possible, investigators should attempt to limit the first step of rescue therapy to topic al 
medications, and escalate to systemic medications only for subjects who do not respond 
adequately after at least 14 days of topi[INVESTIGATOR_35786].   
Subjects who receive topi[INVESTIGATOR_483579] (TCS of any WHO class [see Appendix 8], or 
TCI) will continue treatment with IMP  (tralokinumab/placebo) and will  receive the vaccines . 
TCI may be used for rescue, but should be reserved for body areas where TCS is not 
advisable or on areas where continued treatment with TCS is  considered unsafe.  
If a subject receives rescue treatment with systemic corticost eroids or non -steroidal systemic 
immunosuppressive drugs (cyclosporine, methotrexate, mycophenolate mofetil, azathioprine, 
etc.), IMP will be immediately discontinued (see Se ction  10.2.2 , reasons for temporary 
discontinuation of IMP). After the treatment with these medications is completed, IMP may 
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 46 of 123 
be resumed if deemed appropriate by [CONTACT_86206] ’s medical exper t, but not 
sooner than [ADDRESS_621500] efficacy and safety assessments (for 
example disease severity scores  [IGA and EASI] , safety labs) immediately before 
administering any rescue treatment. An unscheduled visit may be used for this purpose, if 
necessary.  
9.[ADDRESS_621501]  receiv es from 3 months prior to screening through 
safety follow -up (Week  30) must be recorded in the subject ’s medical record and the eCRF 
along with  details such as : 
Medication n ame.
Indication .
Start and stop date of administration (i t will also be recorded if the medication
is ongoing ).
Dosage information , including dose  per administration , unit,  and frequency .
Route of administration.
Dose form (cream, lotion, ointment, other) ; this is only required for topi[INVESTIGATOR_483580] .
Similarly, concurrent procedures must also be recorded in the subject ’s medical record and the  
eCRF. The following data will be recorded: name [CONTACT_315765], indication, body location  
(upper limb, lower limb, trunk, head) , and start and stop date. Note: in this trial, only surgi cal 
procedures and procedures related to AD treatment (e.g., phototherapy or bleach baths) will 
be recorded.  
Investigators may prescribe concomitant medications or treatments to provide adequate 
supportive care as deemed necessary, except for medications l isted in Section  9.7. The 
sponsor ’s medical expert [INVESTIGATOR_73371][CONTACT_26237].  
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 47 of 123 
Concomitant medication for  conditions other than AD may be continued throughout the trial 
without any change in dosage whenever possible.  
The following concomitant medications related to AD treatment are permitted from screening 
through safety follow -up (Week  30): 
Oral antibiotics,  antiviral, or antifungal therapy for skin infections as
appropriate.
Stable doses of an emollient (subjects must apply such emollients twice daily
[or more, as needed] for at least 14  days before baseline and throughout trial
participation).
Oral anti-histamines.
9.7 Prohibited medication  
The medications listed in Panel 6 are prohibited during the trial. 
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 48 of 123 
Panel 6: Prohibited medication  
Medication  Prohibited from  Prohibited to  Temporary 
discontinuation 
of IMP 
required  
Topi[INVESTIGATOR_483581], including:  
TCS of any WHO class.
TCI.
PDE -4 inhibitors.Week  -2 
(2 weeks prior to 
randomisation)  Week 16  
(end of treatment)  No 
Use of UVA or UVB, psoralen + 
UVA (PUVA), other phototherapy, 
or tanning beds.  Week  -6 
(6 weeks prior  to 
randomisation)  Week 16  
(end of treatment)  No 
Three or more bleach baths per 
week.  Week  -4 
(4 weeks prior to 
randomisation)  Week 16  
(end of treatment)  No 
Investigational agents other than 
tralokinumab . 3 months or 5  half-lives1 
prior to randomisation  Week 30  
(safety follow -up) Yes 
Immunoglobulin.  3 months or 5  half-lives1 
prior to randomisation  Week 30  
(safety follow -up) Yes 
Blood products.   4 weeks prior to 
screening  Week 30  
(safety follow -up) Yes 
Systemic corticosteroids2 Week  -4 
(4 weeks prior to  
randomisation)  Week 30  
(safety follow -up) Yes 
Systemic treatment for AD with an 
immunosuppressive or 
immunomodulating agent3. Week  -4 
(4 weeks prior to 
randomisation)  Week 30  
(safety follow -up) Yes 
Allergen immunotherapy.  Randomisation  Week 30  
(safety follow -up) Yes 
Vaccination of any kind  (except 
influenza virus vaccines) . 3 months  prior to 
screening  Week 30  
(safety follow -up) Yes 
1)Whichever is longer. For cell -depleting agents, the use is disallowed within 6 months of randomisation .
2)Note: nasal and inhaled corticosteroids are allowed .
3)Examples include cyclosporine, mycophenolate mofetil, azathioprine, methotrexate, Janus kinase inhibitor s,
interferon -gamma, dupi[INVESTIGATOR_12458] , and other biologics.
AD, atopic dermatitis; IMP, investigational medicinal product;  PDE -4, phosphodiesterase 4; TCI, topi[INVESTIGATOR_483582]; TCS, topi[INVESTIGATOR_11977]; UV , ultraviolet; WHO, World Health Organization.  
In case a ny proh ibited treatments are used during the trial, they must be reco rded as 
concomitant medication.   
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 49 of 123 
Refer to Section  9.5 for principles for use of rescue treatment and re -initiation of IMP after 
discontinuation of prohibited systemic rescue treatment.  
9.8 Treatment lo gistics and a ccountability  
9.8.1 Labelling and p ackaging of trial products  
Tralokinumab/placebo  
The IMP will be packaged in individually numbered kits, each containing 1  syringe 
(tralokinumab 150  mg or placebo).  
Primary and secondary packaging materials (syringe and outer carton, respectively) will be 
individually labelled.  
The labelling of IMPs will be in accordance with Annex  13, local regulations and trial 
requirements. Label text will be translated into local languages, as required. The inner lab el 
will be in English.  
Vaccines  
The IMP will be packaged in individually numbered kits, each containing 1  vial 
(meningococcal vaccine) or 1 pre-filled syringe  (Tdap vaccine) . 
Primary and secondary packaging materials ( vial/pre-filled syringe and outer carton, 
respectively) will be individually labelled.  
The labelling of IMPs w ill be in accordance with Annex  13, local regulations and trial 
requirements. Label text will be translated into local languages, as required. The inner lab el 
will be in English.  
Trial site s will be provided with local labels of the vaccines.  
9.8.2 Storage of trial products   
Tralokinumab/placebo  and vaccines  
All LEO supplied IMPs must be stored in a secure and restricted area under the conditions 
specified on the label and remain in the original container until dispensed.  
The IMP must be stored at 2 to 8°C at the site. The temperature during storage must be 
monitored by a calibrated, stationary and continuously monitoring  system. Minimum 
requirement is a calibrated min/max thermometer.  
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.[ADDRESS_621502] their CRA for further guidance:  
Temperature excursion upon receipt or during storage at the trial site.
Damaged kit upon receipt.
Damaged syringe.
Damaged IMP should b e documented via IRT (refer to the IRT online manual for further 
details). Damaged IMP should not be used.  
9.8.3 Drug accountability  
Tralokinumab/placebo  and vaccines  
The investigator is fully responsible for the IMPs (tralokinumab/placebo and vaccines) at the 
trial site and for maintaining adequate control of the IMPs and for documenting all 
transactions with them.  
An inventory must be kept of the IMP administered to each subject randomised in the trial. 
This inventory must be available for inspection during mo nitoring visits and will be checked 
by [CONTACT_483615].  Full drug accountability will be 
performed in the IRT.  
The trial site will maintain trial kit cartons from used kits until reconciliation. The IMP must 
be fully accoun ted for by [CONTACT_421457]. Following 
reconciliation, the trial kit cartons from used kits may be discarded.  
All unused IMP supplied by [CONTACT_421458]. Prior to 
their return, the IMP must be  fully accounted for by [CONTACT_483616]. Accountability must be documented in the IRT.  
Reporting in eCRF  
The following data will be recorded in the eCRF for tralokinumab/placebo:  
Date and time of IMP administration.
Site of IMP injection (upper arm, anterior thigh, or abdomen).
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 51 of 123 
IMP kit numbers.
The following data will be recorded in the eCRF for the vaccines:  
Date and time of IMP administration.
Site of IMP injection (left upper arm, right upper arm,  other  site [will require  a
comment] ).
IMP kit numbers.
9.8.4 Treatment compliance  
All IMP injections (tralokinumab/placebo and vaccines) will be performed by [CONTACT_483617]. Any non -compliance (subject received 
partial dose; subject received no dose) and the reason for the non -compliace will  be recorded  
in the eCRF . 
9.8.[ADDRESS_621503] destruction  
Used pre-filled syringes (tralokinumab/placebo , Tdap vaccine ) and meningococcal vaccine 
vials will be destroyed at  the trial site provided the trial site has procedures in place for such 
IMP destruction; this requires that the trial site is able to issue a certificate of destruction . 
Trial sites which do not have such IMP destruction procedures in place will dispose u sed 
pre-filled syringes (tralokinumab/placebo , Tdap vaccine ) in sharps bins which will be shipped 
to the CMO  at the end of the trial together with used vaccine vials . 
Unused IMP (tralokinumab/placebo and vaccines ), used pre-filled syringes , and used vaccine 
vials returned to the CMO will be destroyed by [CONTACT_483618]/or local requirements.  
9.[ADDRESS_621504] eted the trial, the 
subjects will be treated at the investigator ’s discretion or referred to other physician(s) 
according to standard practice.  Subjects who qualify for the long -term extension trial (see 
Section  7.1) may be offered participation.  
9.[ADDRESS_621505] complaints  
Any defects or issues with the IMP (tralokinumab/placebo/vaccines) as well as any device 
deficiency (including malfunctions, use errors, and inadequate labelling) must be reported to 
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 52 of 123 
Global Pharmacovigilance, LEO on the trial specific (paper) Complaint Form within [ADDRESS_621506] knowledge.  
Critical complaints (defined a s any issue, defect, or device deficiency that has or potentia lly 
could have a serious impact for the subject [e.g., SAE or large particles in the syringe]) m ust 
be reported to Global Pharmacovigilance, LEO within [ADDRESS_621507], issue, or device 
deficiency, including whether it led to an AE. (S)AEs which occur due to a defect or issue 
with the IMP or due to a device deficiency will be reported by [CONTACT_421462]  13.[ADDRESS_621508] be stored at labelled 
conditions unless otherwise instructed; the trial site will be notified whether the device n eeds 
to be returned for further investigati on or may be destroyed.  
Global Pharmacovigilance, LEO contact [CONTACT_73302]:  
Fax number: [PHONE_1914]  
E-mail address: drug.safety@leo -pharma.com
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.[ADDRESS_621509] may withdraw from the trial or permanently discontinue trial treatment at any time  
(prior to first dose or during the treatment period) if the subject, the investigator, or LE O 
considers that it is not in the subject ’s best interest to continue.   
Discontinued subjects will not be replaced.  
10.2 IMP discontinuation rules  
10.2.1  Reasons for permanent discontinuation of IMP  
Subjects will be permanently discontinued from IMP in the event of:  
Anaphylactic reaction or other severe systemic reaction to IMP injection.
An AE that, in the opi[INVESTIGATOR_26335] ’s medical expert,
contraindicates further dosing.
Diagnosis of a malignancy during the trial, excluding carcinoma in situ of the
cervix, or localised squamous or basal cell carcinoma of t he skin.
Evidence of pregnancy.
Any infection that is opportunistic, such as active tuberculosis and other
infections whose nature or course may suggest an immuno -compromised
status.
Severe laboratory abnormalities:
oALT and/or AST values >3x ULN with total  bilirubin >2x  ULN
(unless elevated bilirubin is related to Gilbert -Meulengracht
Syndrome) .
oConfirmed AST and/or ALT >5x ULN (for more than 2 weeks) .
Refer to Section  10.[ADDRESS_621510] discontinuation and to Panel 2 for 
assessments to be performed  at an early termination visit for subjects who discontinue IMP 
permanently.  
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 54 of 123 
10.2.2  Reasons for temporary discontinuation of IMP  
IMP dosing may be temporarily suspended in the event of:  
Other intercurrent illnesses or major surgery.
An infection that requires par enteral treatment with antibiotic, antifungal,
antiviral, anti -parasitic, or anti -protozoal agents.
Treatment with some of the prohibited medications given in Panel 6
(medications requiring temporary discontinuation of IMP are highlighted in the
column ‘Temporary discontinuation of IMP required ’).
IMP dosing may resume after the medication leading to suspension of IMP is discontinued. 
Refer to Section  9.5 for details regarding re -initiation of IMP after discontinuation of systemic 
rescue treatment.  
10.3 Early termination assessments  
Permanent discontinuation of IMP  
Subjects who permanently discontinue IMP for any reason will be asked to attend an early 
termination visit and return to the trial site for 2  additional visits as indicated below (see the 
schedule of trial procedures [Section  4] for data to be collected at these 3 visits). The 
investigator will review any AEs which will be followed up according to Section  13.7, if the 
subject agrees.  
Subjects who permanently discontinue IMP prior to Week  16 will be asked to attend:  
Early termination visit.
Nominal Week 16 visit (16 weeks after randomisation).
Safet y follow -up visit ([ADDRESS_621511] administration of IMP).
Refer to Section  11.[ADDRESS_621512] administration of IMP (see the schedule of trial procedures 
[Section  4] for data to be collected at an early termination visit).  The investigator will review 
any AEs which will be followed -up according to Section  13.7, if the subject agrees.  
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.[ADDRESS_621513] document this in  the site ’s trial records.  
Refer to Section  11.[ADDRESS_621514] fails to return to the trial site for a requi red 
visit:  
The trial site must attempt to contact [CONTACT_483619] s to and/or should continue in the trial.
Before a subject is deemed lost to follow -up, the investigator or designee must
make every effort to regain contact [CONTACT_483620] (where possible,
[ADDRESS_621515] ’s last kn own
mailing address or local equivalent methods). These contact [CONTACT_483621] ’s medical record.
Should the subject continue to be unreachable, they will be considered to have
withdrawn from the trial with a pr imary reason of lost to follow -up.
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 56 of 123 
11Trial assessments  and procedures  
11.1 Overview  
During this trial, subjects will attend a total of 11 or 12  scheduled visits at the trial site. The 
visits and procedures to be carried out at each visit are summarised in the schedule of trial 
procedures ( Panel 2). Refer to Section  7.1 for further details on the trial design.  
Assessments and procedures at each trial visit should be performed in the order shown in 
Panel 7.  
Panel 7: Sequence of assessments  and procedures  
*First component C, then component A and B; ***Week  12 only .
DLQI, Dermatology Life Quality Index; EASI, Eczema Area and Severity Index; EQ-5D-5L, EuroQoL 
5-Dimension Health Questionnaire 5 -Level; HADS, Hospi[INVESTIGATOR_5620]; IGA, Investigator’s
Global Assessment; IMP, investigational medicinal product; POEM, Patient Oriented Eczema Measure; 
SCORAD, Scoring Atopic Dermatitis.  Patient -reported outcomes
1) DLQI
2) EQ -5D-5L
3) POEM
4) HADS
Investigator assessments
1) SCORAD*
2) IGA
3) EASI
Safety and laboratory assessments
Administration of IMP (vaccines)**
Administration of IMP 
(tralokinumab/placebo)
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.[ADDRESS_621516] documented experience 
and/or training in use of the assessments required by [CONTACT_483622] b e either a 
physician, certified physician ’s assistant, or advanced registered nurse practitioner. AEs must 
be assessed by [CONTACT_82048] (Section  13.2). 
The investigators performing the assessments must not be involved in the administration of 
IMP (tralokinumab/placebo). See Section  9.3.[ADDRESS_621517] throughout the entire trial period , if possible . 
During t he course of the trial, subjects may need to be seen at unscheduled visits. The 
assessments to be performed at an unscheduled visit are left to the investigator ’s discretion  
(could include any assessment performed at an early termination visit).  Refer to t he schedule 
of trial procedures ( Panel 2) for assessments to be considered at an unscheduled visit.  
11.2 Assessments performed only at screening/baseline  
11.2.1  Demographics  
The following demographic data will be recorded:  
Age: date, m onth and year of birth . Where it is not allowed to collect the subject ’s
full date of birth, only month  and/or year of birth will be collected  as per local
legislation . In these cases, the subject ’s age in years will also be recorded.
Sex: female, male .
Race: American Indian or Alaska native, Asi an (Japanese) , Asian (others), black or
African American, native Hawaiian or other Pacific islander, white, other.
Ethnic origin (self -reported by [CONTACT_423]): Hispanic or Latino, not Hispanic or
Latino .
11.2.[ADDRESS_621518] be recorded and includes:  
Skin disease history: all past and current skin disease history including:
oAlopecia
oVitiligo
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 58 of 123 
oHerpes simplex
Atopy history:
oDuration of AD in years
oPrevious AD treatments
oAsthma
oFood allergy
oHay fever
oAllergic conjunctivitis
oAtopic keratoconjunctivitis
oEczema herpeticum
Other medical and surgical history, including concurrent diagnoses.
Relevant medical history includes also diseases which are specifically listed as exclusion 
criteria and diseases for which specific treatments are listed as exclusion criteria.  
For each condition, diagnosis , or surgical procedure, the start date and stop date will be 
recorded; it will als o be recorded if the condition, diagnosis , or surgical procedure is ongoing.  
11.2.[ADDRESS_621519] ’s height (without shoes) will be measured; the subject ’s weight (in indoor 
clothing and without shoes) will be measured . 
11.2.4  Body surface area involvement 
The total BSA affected by [CONTACT_483623] A of SCORAD (see Section  11.3.3 ) and will b e reported as a percentage of all 
major body sections combined. The following body regions will be assessed (brackets show 
the highest possible score for each region): head and neck (9%), anterior trunk (18%), back 
(18%), upper limbs (18%), lower limbs (36 %), and genitals (1%). The total BSA will be 
assessed according to the schedule of trial procedures (Section  4). 
11.2.5  Columbia -Suicide Severity Rating Scale  
The C -SSRS Screening version is a rater -administered instrument used to assess severity of 
suicidal ideation and suicidal behaviour through a series of simple, plain -language 
questions  (25). The C -SSRS must be completed at the screening visit to che ck that exclusion 
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 59 of 123 
criterion no.  25 does not apply.  Further details on th e assessment acc ording to the C -SSRS are 
included in the efficacy assessment & C -SSRS manual.  
11.3 Efficacy assessments  
11.3.1  Investigator ’s Global Assessment  
The IGA is an instrument used in clinical trials to rate the severity of the subject ’s global AD 
and is  based on a 5 -point scale ranging from 0 (clear) to 4 (severe)  (Panel 8). The IGA score 
will be assessed according to the schedule of trial procedures (Section  4). The assessment will 
be based on the condition of the disease at the time of evaluation and not in relation to the 
condition at a previous visit.  The IGA is included in the efficacy assessment & C -SSRS 
manual . 
Panel 8: Investigator ’s Global Assessment  
Score  Disease severity  Standard IGA scale  IGA morphological descriptors  
0 Clear  No inflammatory signs of atopic 
dermatitis  No erythema and no elevation 
(papulation/infiltration).  
[ADDRESS_621520] perceptible 
papulation/infiltration  Barely perceptible erythema 
and/or minimal lesion elevation 
(papulation/infiltration) that is not 
widespread.  
2 Mild disease  Mild erythema a nd mild 
papulation/infiltration  Visibly detectable, light pi[INVESTIGATOR_421422] 
(papulation/infiltration).  
3 Moderate 
disease  Moderate erythema and 
moderate papulation/infiltration  Dull red, clearly distinguishable 
erythema and clearly perceptible 
but not extensive elevation 
(papulation/infiltration).  
4 Severe disease  Severe erythema and severe 
papulation/infiltration  Deep/dark red erythema, marked 
and extensive elevation 
(papulation/infiltration).  
11.3.2  Eczema Area and Severity Index 
The EASI is a validated measure used in clinical practice and clinical trials to assess the 
severity and extent of AD ( 26). The EASI score will be assessed according to the schedule of 
trial procedures (Section  4). The assessment will be based on the condition of the disease at 
the time of evaluation and not in relation to th e condition at a previous visit . 
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 60 of 123 
The EASI is a composite index with scores ranging from 0 to 72, with higher values 
indicating more severe or more extensive condition . The index will be calculated as shown in 
Panel 9. Briefly, t he investigato r will assess the severity of 4  AD disease characteristics 
(erythema, induration/papulation, excoriation, and lichenification) on the 4 body regions 
(head/neck, trunk , upper extremities , lower extremities ); severity will be assessed according 
to the scale shown in Panel 10. For each body region, a severity sum score will be calculated 
which will be multiplied by [CONTACT_73307] (Panel 10) and by a weigh ting factor . The EASI 
score equals the sum of the scores obtained for each body region ( Panel 9). Refer to the 
efficacy assessment & C -SSRS manual for further d etails  on these assessments . 
Panel 9: Calculation of the Eczema Area and Severity Index  
Body region  
Erythema  
Induration / 
papulation  
Excoriation  
Lichenification  
Area score  
Weigh ting factor  
Score  
Head/ neck  ( SS   +     SS   +     SS   +     SS ) x  AS  x 0.1  
Trunk  ( SS   +    SS   +     SS   +     SS ) x  AS  x 0.3  
Upper extremities  ( SS   +     SS   +     SS   +     SS ) x  AS  x 0.2  
Lower extremities  ( SS   +     SS   +     SS   +     SS ) x  AS  x 0.4  
The EASI score is the sum of the 4 body region scores  
(range 0-72) 
AS, area score; EASI,  Eczema Area and Severity Index ; SS, severity score. Modified from ( 27). 
Panel 10: EASI severity score scale and area score scale  
Severity score scale  Area score scale  
0 None/absent  0 0% affected area  
1 Mild  1 1% to 9% affected area  
2 Moderate  2 10% to 29% affected area  
3 Severe  3 30% to 49% affected area  
Note: h alf-steps (0.5, 1.5, 2.5) are 
allowed.  4 50% to 69% affected area  
5 70% to 89% affected area  
6 90% to 100% affected area  
EASI, Eczema Area and Severity Index . 
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 61 of 123 
11.3.3  Scoring Atopic Dermatitis  
The SCORAD is a validated tool to evaluate the extent and severity of AD  lesions,  along with 
subjective symptoms  (28). The maximum total score is 103, with higher values indicating 
more severe disease. SCORAD will be assessed according to the schedule of trial procedures 
(Section  4). Refer to the efficacy assessment & C -SSRS manual for further d etails  on these 
assessments .  
The assessment will be based on the condition of the disease at the time of evaluation and not 
in relation to the condition at a previous visit.  
The assessment consists of 3 components: A = extent , B = intensity , and C = subjective 
symptoms .  
Extent (A)  
The extent  of AD is assessed as a percentage of each defined body area and reported as the 
sum of all areas (maximum score = 100%)  
Intensity (B)  
The intensity  of 6 specific symptoms of AD (erythema, edema/p apulation, oozing/crusting , 
excoriation, lichenification , and dryness) is assessed by [CONTACT_421468]:  
0 = None/absent  
1 = Mild 
2 = Moderate  
3 = Severe  
Note: dryness is evaluated on uninvolved areas.  
The sum of intensity score of the 6 symptoms  will be reported (maximum score = 18 ). 
Subjective symptoms (C)  
A subjective assessment of the average itch and sleeplessness over the last 3  days/nights is 
recorded for each symptom by [CONTACT_1175] a visual analogue scale , where 0 is no itch (or 
sleeple ssness) and [ADDRESS_621521] imaginable itch (or sleeplessness), with a maximum 
possible score of 20.  
The SCORAD is calculated  as: A/5+7B/2+C  
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 62 of 123 
11.3.4  Patient -reported outcomes  
[IP_ADDRESS]  Dermatology Life Quality Index  
The DLQI is a validated questionnaire with content specific to those with dermatology 
conditions. It consists of [ADDRESS_621522] ’s perception of the impact of their 
skin disease on different aspects of their H RQoL over the last week such as 
dermatology -related symptoms and feelings, daily a ctivities, leisure, work or school, personal 
relationships, and the treatment ( 29). Each item is scored on a 4 point Likert scale (0 = ‘not at 
all ⁄not relevant ’; 1 = ‘ a little ’; 2 = ‘ a lot’; 3 = ‘ very much ’). The total score is the sum of the 
10 items (0 to 30); a high score is indicative of a poor H RQoL. The DLQI will be completed 
according to the schedule of trial procedures in Section  4. It will be completed electronically 
on the device supplied to the trial site and is included in the investigator trial file.  
[IP_ADDRESS]  EQ-5D-5L 
The EQ -5D-5L is a standardised measure of health statu s developed by [CONTACT_483624] a simple, generic measure of health for clinical and economic appraisal ( 30). The 
EQ-5D-5L is a self -administered quest ionnaire used to assess health status ‘today ’ and is 
divided into 2  sections: The first section includes 5  dimensions (mobility, self -care, usual 
activity, pain/discomfort, and anxiety/depression); each dimension will be assessed by [CONTACT_483625] a 5 -point scale (‘no problems ’, ‘slight problems ’, ‘moderate problems ’, ‘severe 
problems ’, and ‘extreme problems ’). The second section consists of a vertical visual analogue 
scale anchored at 0 (‘the worst  health you can imagine ’) and 100 (‘the best health you can 
imagine ’). The EQ -5D-5L will be completed according to the schedule of trial procedures in 
Section  4. It will be completed electronically on the device supplied  to the trial site and is 
included in the investigator trial file.  
[IP_ADDRESS]  Patient -Oriented Eczema Measure 
The POEM  is a validated questionnaire used to assess disease symptoms in atopic eczema 
patients in both clinical practice and clinical trials ( 31). The tool consists of 7  items , each 
addressing a specific symptom (itching, sleep, bleeding, weepi[INVESTIGATOR_007], cracking, flaking, and 
dryness). Subject s will score how often they have experienced each symptom over the 
previous week on a 5 -point categorical response scale (0  = ‘no days ’; 1 = ‘1 to 2 days ’; 2 = ‘3 
to 4 days’; 3 = ‘5 to 6’ days; 4  = ‘every day ’). The total score is the sum of the 7  items (ra nge 
0 to 28) and reflects disease -related morbidity; a high score is indicative of a worse disease 
severity. The POEM will be completed according to the schedule of trial procedures in 
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 63 of 123 
Section  4. It will be completed electronically on the device supplied to the trial site and is 
included in the investigator trial file.  
[IP_ADDRESS]  Hospi[INVESTIGATOR_80156] a Likert -scale tool widely used to detect states of anxiety and depression in a 
general hospi[INVESTIGATOR_6885] ( 32). The tool consists of [ADDRESS_621523] ’s anxiety (7 
items) and depression (7 items) du ring the last week. Each question is scored from 0 to 3, 
with high scores indicating a poor state. The HADS will be completed electronically on the 
device supplied to the trial site according to the schedule of trial procedures (Section  4) and is 
included in the investigator trial file.  
11.4 Safety assessments  
11.4.1  Vital signs 
Vital signs (resting blood pressure, pulse,  and body temperature) must be assessed according 
to the schedule of trial procedures (Section  4). Vital signs will be measured in a supi[INVESTIGATOR_483583] [ADDRESS_621524] should be r andomis ed 
into the trial  (respecting exclusion criterion  no. 27).  
In case of abnormal findings , the vital sign measurement c an be repeated approximately 
[ADDRESS_621525] measurement verifies the second (normal) value, the first measuremen t 
should be considered false. If the third measurement confirms the first measure ment 
(abnormal) , the second measurement will be considered false. Only the last value measured 
and considered correct will be recorded in the eCRF.  
Reporting in eCRF  
Vital signs and the date and time they were measured will be recorded in the eCRF. Clinica lly 
significant a bnormal vital signs at the (first) screening visit will be documented as medical 
history in the eCRF. If an abnormal vital sign at any other visit than the first screening visit is 
considered by [CONTACT_483626] t, it will be reported as an AE in 
accordance with Section  13.3. Further, any clinically significant deterioration of a pre -existing 
condition as well as any new clinically significant sign, symptom or illness observed after 
screening will be reported as an AE in accordance with Section  13.3. 
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.[ADDRESS_621526] including whole body inspection of the skin 
and ausculta tion of heart, lungs and abdomen; palpation of the abdominal organs and basic 
neurological status must be performed according to the schedule of trial procedures 
(Section  4). 
If an unacceptable abnormal finding is identified during the physical examination at the 
screening visit, the subject must not be randomised into the clinical trial (respecting exclusion 
criterion no.  27) 
Reporting in eCRF  
It will be recorded in the eCRF if a physical examination was performed and, if applicable, 
the investigator ’s assessment of the result (‘normal ’, ‘abnormal, not clinically significant ’, 
‘abnormal, clinically significant ’). If a physical examination was not performed, a reason 
should be given.  
Clinically significant abnormal physical examination findings at the (first) screening visit will 
be documented as medical history in the eCRF. If an abnormal physical examination finding 
at any other visit than the first screening visit is considered by [CONTACT_421472], it will be reported as an AE in accordance with Section  13.3. Further, any 
clinically significant deterioration of a pre -existing condition as well as any new clinically 
significant sign, symptom or illness observed after screening will be reported as an AE in 
accordance with Section  13.3. 
11.4.[ADDRESS_621527] 5  minutes at the visits indicat ed in the schedule of trial procedures (Section  4). 
A pre -evaluation of the ECGs will be performed by [CONTACT_483627]. At a minimum, date of ECG collection will be recorded in the source 
documents.  
The ECG data will be transferred to a central ECG service company for central evaluation. A 
cardiologist at the ECG service company will analyse and interpret the ECG data. The ECG 
service company will provide ECG evaluation reports to the trial sites.  
The investigator must evaluate all abnormal ECG results (‘clinically significant ’ or ‘not 
clinically significant ’) and sign and date. The investigator has the final decision on the clinical 
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 65 of 123 
significance of ECG abnormalities. If a result is abnormal at the screening visit and  
considered by [CONTACT_11150], it will be up to the investigator ’s 
discretion if the subject should be enrolled into the trial (respecting exclusion criterion 
no. 27); if such a subject is enrolled, the investigator will provide a justification in the medical 
record.  
The collection and transmission of ECG data will be described in a separate ECG manual. 
Test dummy t ransmissions will be undertaken prior to trial conduct to ensure that 
transmissions can be made and that date and time settings are correctly set.  
Reporting in eCRF  
It will be recorded in the eCRF if an ECG was performed and, if applicable, the investigato r’s 
assessment of ECG results ( ‘normal ’, ‘abnormal, not clinically significant ’, ‘abnormal, 
clinically significant ’). If an ECG was not performed, a reason should be given.  
Clinically significant abnormal ECG findings at the (first) screening visit will be  documented 
as medical history in the eCRF. If an abnormal ECG  at any other visit than the first screening 
visit is considered by [CONTACT_11150], it will be reported as an AE 
in accordance with Section  13.3. Further, any clinically sig nificant deterioration of a 
pre-existing condition as well as any new clinically significant sign, symptom or illness 
observed after screening will be reported as an AE in accordance with Section  13.3. 
11.4.[ADDRESS_621528] (human chorionic gonadotropin; dipstick) must be performed at the 
trial site at baseline prior to randomisation in female subjects of child -bearing potential. The 
test must be repeated every [ADDRESS_621529] will be recorded in the eCRF 
(‘positive ’, ‘negative ’). 
Note that pregnant subjects must discontinue IMP immediately (Section 10.2.1 ). 
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 66 of 123 
11.4.5  Laboratory  testing  
Samples for laboratory testing will be collected according to the schedule of trial procedures 
(Section  4). 
The following safety samples will be analysed by a central laboratory: chemistry, 
haematology, serology, and serum pregnancy  (Panel 11).  
Urine samples will be tested at the trial site with a dipstick; if abnormal, a urine sample will 
be sent to the central laboratory for further analysis.  
A laboratory manual will be provided to the sites that specifies the procedures for collection, 
processing, storage, destruction, and shipment of samples, as well as laboratory contact 
[CONTACT_483628].  
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 67 of 123 
Panel 11: Clinical laboratory tests  
Chemistry  Haematology  
Sodium  
Potassium  
Creatinine  
Urea nitrogen  
Calcium  
Alkaline phosphatase  
Aspartate aminotransferase  
Alanine aminotransferase  
Gamma glutamyl transferase 
Bilirubin1 
Lactate dehydrogenase  
Cholesterol  
LDL  cholesterol  
HDL  cholesterol  
Triglycerides  
Glucose (non -fasting)  
Albumin  
Protein  
Tryptase2 Erythrocytes  
Hematocrit  
Hemoglobin  
Erythrocyte m ean corpuscular volume  
Erythrocyte m ean corpuscular haemoglobin 
concentration  
Leukocytes   
Neutrophils    
Neutrophils/ leukocytes  
Lymphocytes   
Lymphocytes/ leukocytes  
Monocytes   
Monocytes/ leukocytes  
Eosinophils  
Eosinophils/ leukocytes  
Basophils  
Basophils/leukocytes  
Thrombocyte s  
Serology  
Hepatitis B virus surface antigen4
Hepatitis B virus surface antibody4 
Hepatitis B virus core antibody4 
Hepatitis C virus antibody4 
HIV-1 antibod y4
HIV-2 antibod y4
Immunoglobulin E5 
Urinalysis3 Serum pregnancy test4,6 
Protein  
Glucose  
Ketones  
Occult b lood 
Leukocytes  
Nitrite  Choriogonadotropin beta  
1)If bilirubin is above upper limit of normal, direct and indirect bi lirubin will also be measured.
2)Only measured in case of suspected anaphylaxis (Section  9.2.1 ).
3)Urine samples will be tested at the trial site (dipstick). In case of abnormal dipstick results, a urine sample
will be sent to the central laboratory for microscopic examination (leukocytes, erythrocytes, and casts).
4)Measured at screening only.
5)Not measured at screening.
6)Only female subjects of child -bearing potential .
HDL, high density lipoprotein; HIV , human immunodeficiency virus; LDL, low density lipoprotein.
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.[ADDRESS_621530] evaluate all results outside the reference range (‘clinically signific ant’ 
or ‘not clinically significant ’) and sign and date. The signed and dated version will be fil ed 
with the investigator ’s trial documentation. Clinically significant abnormal te sts at baselin e 
(Week 0) or later must be repeated to confirm the abnormality.  
If a screening laboratory result is abnormal and of clinical significance, it will be at the 
investigator ’s discretion to decide if the subject should be enrolled into the trial  (respecting 
exclusion criteria  no. 27, 28, and 29). 
Reporting in eCRF  
At each visit, the site staff will record the following in the eCRF: Date and time of blood 
sample (or that a blood sample  was not taken ) and the investigator ’s assessment of the results 
(‘normal ’, ‘abnormal, not clinically significant ’, ‘abnormal, clinically significant ’). In 
addition, the site staff will record in the eCRF if a urine sample was taken and the 
investigator ’s assessment of the result (‘normal ’, ‘abnormal ’). 
Clinically significant abnormal laboratory findings a t the (first) screening visit will be 
documented as medical history in the eCRF. If an abnormal laboratory finding at any other 
visit than the first screening visit is considered by [CONTACT_11150], 
it will be reported as an A E in accordance with Section  13.3. Further, any clinically significant 
deterioration of a pre -existing condition as well as any new clinically significant sign, 
symptom or illness observed after screening will be reported as an AE in accordance with 
Section  13.3. 
11.4.6  Anti -drug antibodies measurements 
Blood samples will be col lected for determination of anti -tralokinumab antibody levels at 
pre-determined time points according to the schedule of trial procedures (Section  4).  
It will be r ecorded in the eCRF if the ADA sample was taken; if not, a reason will be 
provided.  
Collection, handling and shipment instructions for ADA blood samples are provided in a 
separate laboratory manual.  
Serum samples for determination of presence or absence of ADA will be analysed by a 
laboratory using a validated bioanalytical method. A tiered testing scheme will be employed, 
with the first step being screening. Samples found positive in the screening step will be tested 
in the confirmatory step. Samples confi rmed positive for ADA in the confirmatory step will 
undergo endpoint titre determination and will be analysed for the presence of neutralising 
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 69 of 123 
antibodies (nAB). Details of the analytical method used will be described in the ADA 
bioanalytical report.  
11.5 Assessment of v accine responses  
Blood samples for assessment of vaccine -specific serum antibody responses will be collected 
at the time points specified in the schedule of trial procedures (Section  4). 
Collection, handling and shipment instructions for these  blood samples are provided in a 
laboratory manual.  
The antibody response to Tdap vaccine will be a ssessed by [CONTACT_483629] -tetanus IgG 
by [CONTACT_260694].  The antibody response to meningococcal  vaccine will be assessed by 
[CONTACT_483629] -meningococcal IgG by [CONTACT_260694] . 
Reports of serum antibody responses will be provide d by [CONTACT_483630] . The investigator must sign and date  these reports . 
Reporting in eCRF  
It will be recorded in the eCRF if the blood sample s to assess vaccine response were taken; if 
not, a reason will be provided.  
11.6 Pharmacokinetic assessments  
Blood samples for PK assessments mus t be collected at the time points specified in the 
schedule of trial procedures (Section  4). 
It will be recorded in the eCRF if the PK sample was taken; if not, a reason will be provided . 
Collection, handling and shipment instructions for PK blood samples are provided in a 
laboratory manual.  
Serum samples for determination of tralokinumab concentrations will be analysed by a 
laboratory using a validated bioanalytic al method. Details of the analytical method used wil l 
be described in the bioanalytical report.  
11.7 Pharmacodynamic s and pharmacogenomics  
Not applicable.  
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 70 of 123 
11.8 Other assessments  
Not applicable.  
11.9 Estimate of total blood volume collected  
Blood samples will be drawn for chemistry, haematology, serology, PK, ADA, and 
vaccine -specific serum antibody responses . The total volume of blood to be drawn is 
approximately 150 mL which is less than the volume of blood drawn during a blood donation 
(approximately 500 mL).  
11.10  End of trial  
An end -of-treatment form and an end -of-trial form will be compled in the eCRF for all 
randomised subjects , including  subjects who permanently discontinue IMP and subjects who 
withdraw from trial (see Section  10.3 for early termination assessments).  
End-of-treatment form  
An end -of-treatment form will be completed when the subject has had their last 
administration of IMP . The following data will be recorded on this form:  
Date of last administration of IMP (tralokinumab/placebo).
Has the subject completed the treatment period (yes/no).  If no, the primary
reason for permanent discontinuation of IMP must be recorded (lack of
efficacy, AE, withdrawal by [CONTACT_1130], lost to follow -up, death, other).
The primary reason for permanent discontinuation of IMP must also be recorded in the 
medical records.  
End-of-trial form  
An end -of-trial form will be completed when the subject has had their last visit.  The following 
data will be collected:  
Did the subject complete the trial  (yes/no) .
Has the su bject been transferred to LP016 2-1337 (yes/no). If yes, the site will
record the last visit the subject attended , including phone calls (Week  16,
Week  20, Week  24, Week  30, unscheduled visit).
Did the subject attend the nomi nal Week  16 visit  (yes/no) . If no, the primary
reason for not attending the visit must be recorded (lack of efficacy, AE,
withdr awal by [CONTACT_1130], lost to follow -up, death, other) .
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 71 of 123 
Did the subject attend the safety follow -up visit  (yes/no). If no, the primary
reason for not attending the visit must be recorded ( lack of efficacy , AE,
withdr awal by [CONTACT_1130], lost to follow -up, death, transferred to LP0162 -1337,
other).
Date of last contact .
Primary reason for withdrawal  from trial (lack of efficacy, adverse event,
withdrawal by [CONTACT_1130], lost to follow -up, death, other).
11.11  Storage of biological samples  
The samples analysed by [CONTACT_2237] ( Panel 11) will be destroyed after analysis.  
PK samples will be retained for as long as the quality of the material permits evalu ation but  
for no longer than 12  months after completion of the CTR.  
Samples for ADA evaluation will be retained for as long as the quality of the material permi ts 
evaluation  but for no longer than 15  years after marketing authorisation.  
Samples collected to assess the v accine -specific antibody response will be retained fo r as lon g 
as the quality of the material permits evaluation but for no longer than 12  months after 
completion of the CTR.  
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.[ADDRESS_621531] 2 different vaccines (a combined 
diphtheria, tetanus, and acellular pertussis  vaccine and a meningococcal vaccine ) in adults 
with moderate -to-severe AD who are treated with tralokinumab , to ensure a broad assessment 
of immune competence in subjects treated with  tralokinumab.  
Since concomitant administration of vaccines may affect the efficacy of tralokinumab in 
patients with AD, a placebo -controlled parallel group design has been chosen to evaluate the  
efficacy and safety of Q2W tralokinumab concomitantly administered with vaccines in the 
target patient population.  
The vaccines will be given after 12  weeks of tralokinumab /placebo  treatment to ensure that 
the trial drug effect has reached near -steady state levels when the vaccines are administered.  
The vacci ne responses will be analysed at Week 16 when the tralokinumab /placebo  treatment 
schedule is complete. This allows an evalua tion of the vaccine responses 4  weeks after 
vaccination which is the time span used to evaluate efficacy of these vaccine 
products  (33, 34). 
The trial will evaluate the percentage of sub jects achieving a positive anti -tetanus response  at 
Week  16 (defined as a 3-fold IgG increase compared to Week  12 if IgG  ≤1.0 IU/mL at 
Week  12; or IgG  ≥2.5 IU/mL if IgG  >1.0 IU/mL at Week  12) and a positive 
anti-meningococcal response at Week  16 (defined as IgG ≥3.0 mcg/mL with at least a 3 -fold 
increase compared to Week  12). These response criteria were developed based on the criteria 
for positive vaccine response in the assays used for determining anti-tetanus and 
anti-meningococcal IgG concentrations. The anti-tetanus res ponse definition takes into 
account that some subjects may have high pre -vaccination anti -tetanus IgG levels and may 
therefore not be able to elicit the same increase in anti -tetanus IgG levels as those with l ow 
pre-vaccination levels . 
The results should b e generalisable to an adult population with AD. The age limit of 54  years 
is chosen to ensure that no subjects older than the meningococcal vaccine age limit of 
55 years are included . 
Subjects who do not achieve or lose clinical response will not be exclud ed from further 
participation in the trial. This approach has been chosen to increase the likelihood that 
subjects from the placebo arm will stay in the trial until administration of the vaccines 
(Week  12) and evaluation of the vaccine responses (Week  16). Subjects who complete the 
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 73 of 123 
Week  16 visit may be invited for the open -label, long -term extension trial  conducted under a 
separate clinical trial protocol  (ECZTEND) . 
The clinical efficacy of tralokinumab treatment will be assessed by [CONTACT_78442], EASI, and  
SCORAD. IGA is a key instrument used in clinical trials to rate the severity of the  subject ’s 
global AD.  EASI is a validated measure used in clinical practice and clinical trials to  assess 
the severity and extent of AD ( 26). SCORAD is a validated tool to assess the extent and 
severity of AD lesions  and subjective symptoms ( 28). 
The e fficacy endpoints IGA score of [ADDRESS_621532] tralokinumab (ADAs) will be collected and the potential for  
immunogeni city will be evaluated until [ADDRESS_621533] dose of tralokinumab, to  
ensure adequate washout (approximately 5  times the half -life). The serum samples for  
determination of presence or absence ADA will be analysed using a validated bioanalytical  
method. 
Safety will be assessed using standard clinical methods of subject evaluations, such as AE 
monitoring, ECG, vital sign and clinical laboratory measurements.  
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 74 of 123 
13 Adverse e vents  
13.1 Definition and classification  of adverse events  
Adverse events ( AEs) and serious adverse events (SAEs) are defined in  Appendix 1. 
Classification of AEs in terms of severity, causality and outcome  is defined in Appendix 2. A 
causality assessment will be made for both tralokinumab/placebo and each of the vaccines.  
13.[ADDRESS_621534] has signed the 
informed c onsen t form (ICF) until completion of the clinical trial (defined as per Section  7.3). 
AEs must be assessed by [CONTACT_82048].  
At all visits, the subject will be asked a non -leading question by [CONTACT_73318], 
for example : “How have you felt since I saw you last?” No specific symptoms should  be 
asked for. It is important that the investigator  also observes the subject for any changes no t 
reported by [CONTACT_73319].  
Refer to Sections 11.4.[ADDRESS_621535] be recorded on the AE form 
of the eCRF and should be d escribed in the following manner:  
The AE term  must  be in precise English medical terminology ( that is, not necessarily the exact 
words used by [CONTACT_423]). Whenever possible, a specific diagnosis should be stated ( for 
example  ‘allergic contact [CONTACT_8748] ’). 
The duration  of the AE must  be reported by [CONTACT_73320]  (it will 
also be recorded if the event is ongoing) . In addition, it will be recorded if the AE started prior 
to first dose of IMP  (tralokinumab/placebo); it will also b e recorded if the AE started prior to 
administration of the vaccines . 
AEs must be classified in terms of severity, causality and outcome according to the definitions 
in Appendix 2. 
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 75 of 123 
Action taken with IMP: any action taken with IMP as a consequence of the AE must  be 
recorded (dose not changed, dose reduced, dose increased, drug interrupted, drug wit hdrawn, 
not applicable, un known ). 
Other action taken:  any other action taken as a result of the AE must  be recorded ( none, 
concomitant med ication, concurrent  procedure).  
13.4 Reporting of serious adverse events  
The criteria that define an AE as serious ( that is , an SAE) are defined in Appendix 1. SAE 
criteria are also listed on the SAE f orm. 
13.4.[ADDRESS_621536] be reported to LEO on the (paper) SAE Form within [ADDRESS_621537] 
knowledge. This report should contain an assessment of available information on seriousness,  
severity, causal relationship to the IMP  (tralokinumab/placebo), IMP (vaccines), IMP device, 
or trial procedure, the action taken, the outcome to date, a nd a narrative description of th e 
course of the event.  
The completed SAE form must be faxed or scanned and e -mailed to Global 
Pharmacovigilance at  LEO using the e-mail address or fax number  below : 
Global Phar macovigilance at  LEO  
E-mail address: drug.safety @leo -pharma.com
Fax number: [PHONE_1914]  
If relevant, the investigator will enclose other information with the SAE form, such as 
anonymised reports of diagnostic procedures, hospi[INVESTIGATOR_1097], autopsy reports, etc.  
Addition ally, Global Pharmacovigilance at LEO may request further information in order to 
fully assess the SAE. The investigator must forward such information to LEO upon request by 
[CONTACT_3719] e -mail (see contact [CONTACT_73322]).  
The investigator must notify the local IRB(s) of SAEs , as required by [CONTACT_483631].  
SAEs occurring after the completion of the clinical trial (defined as per Section  7.3) should 
not be routinely sought or collected. However, such events should be reported to Global 
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 76 of 123 
Pharmacovigilance  at LEO ( see contact [CONTACT_73322] ) if the investigator becomes aware of 
them.  
13.4.2  LEO r eporting responsibilities  
Global Pharmacovigilan ce at LEO is responsible for assessing whether or not an SAE is 
expected. The relevant reference  safety information document s for this clinical trial are:  
For the IMP  (tralokinumab/placebo) , the In vestigator ’s Brochure, edition  [ADDRESS_621538] be used.
For the IMP ( Tdap and meningococcal vaccines) , the latest version of the
approved labelling in the US must be used .
Global Pharmacovigilance at LEO will notify the regulatory authorities and concerned 
investigators of SAEs according to the c urrent applicable legis lation for the concerned 
countr ies.  
The IRB(s)  will be notified of SAEs according to the current applicable legis lation for the 
concerned countr ies.  
For all countries  except the US , the following  reporting requirements apply: a ll SAEs which 
are assessed as causally related to the IMP(s) by [CONTACT_121580]  (ICH E2A 
Guideline), and which are unexpected (Suspected, Unexpected Serious Adverse Reactions 
[S[LOCATION_003]Rs] ), are subject to expedited repor ting to regulatory author ities and IRB(s)  according 
to the current applicable legis lation in the concerned countr ies. Investigators will be noti fied 
of the evolving safety profile of the IMP  on an ongoing basis.  
For the US, the following  reporting requirements apply: a ll SAEs whic h are assessed  as 
causally related to the IMPs  by [CONTACT_82093]  (Guidance for Industry and Investigators - Safety 
Reporting Requirements for INDs and BA/BE Studies ; Guidance for Clinical Investigators, 
Sponsors, and IRBs: Adverse Event Reporting to IRBs – Improving Human Subject 
Protection ) and which are unexpected (Serious and Unexpect ed Suspected Adverse Reactions 
[IND safety rep ort]) are subject to expedited repor ting to regulatory authorities and IRB(s) . 
Investigators will be notified of  the evolving safety profi le of the IMP  on an ongoing basis . 
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.[ADDRESS_621539] knowledge using t he (paper) Pregnancy Form (Part  I). All pregnancies must be followed 
up until delivery or termination and final outcome must be reported on t he (paper) Pregnancy 
Form (Part  II) within [ADDRESS_621540] immediately discontinue IMP permanently (Section s 10.2.1  and 10.3). 
13.[ADDRESS_621541] 
results, if applicable. An AESI may be serious (requiring expedited reporting, Section 13.4) or 
non-serious.  
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 78 of 123 
Panel 12: Adverse events of special interest  
Adverse event of special interest  Additional information to be provided 
Eczema herpeticum  Skin findings: 
Lesion type  (papules, vesicles, cru sts, eroded
pi[INVESTIGATOR_10022], other) .
Disseminated / localised.
Location  (face, scalp, back, chest, upper
limb, lower limb, genitals) .
Present in an area with visible eczema / no
visible eczema / present in areas with and
without eczema.
Monomorphic / polymorphic.
Confirmation of herpes simplex virus  (not confirmed, 
PCR, viral culture, Tzanck, other)  
Malignancies diagnosed after 
randomisation, excluding basal cell 
carcinoma, localised squamous cell 
carcinoma of the skin, and 
carcinoma in situ of the cervix  Histology report  available
Oncology assessme nt available
Treatments (surgery, radiation,
chemotherapy, other)
Skin infections requiring systemic 
treatment  Location (face, scalp, back, chest, upper
limb, lower limb, genitals)
Outcome of pathogenic skin swab  (positive,
negative, not performed)
Conjunctivitis  Aetiology (viral, bacterial, allergic,
unknown)
Bacterial culture outcome (for events with
bacterial aetiology)
Diagnosis confirmed by [CONTACT_483632]  Aetiology (infectious,  non -infectious, other,
unknown)
Bacterial culture outcome (for events with
bacterial aetiology)
Diagnosis confirmed by [CONTACT_483633]  Aetiology (infectious,  non -infectious, other,
unknown)
Bacterial culture outcome (for events with
bacterial aetiology)
Diagnosis of herpes simplex kera titis (for
events with viral aetiology)
Diagnosis confirmed by [CONTACT_483634]-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.[ADDRESS_621542] receiving a dose of IMP in excess of that specified in t his 
protocol.  
The term ‘overdose ’ must be recorded on the AE form of the eCRF. In addition, AEs 
originating from overdose must be recorded as separate events. If an AE originating from an 
overdose qualifies as an SAE, expedited reporting is required (Section 13.4). 
LEO does not recommend specific treatment for an overdose. The investigator will use 
clinical judgment to treat any overdose if necessary.  
13.6.[ADDRESS_621543]. Broadly, medication errors fall into 
4 categories: wrong medication, wrong dose (including strength, form, concentrat ion, 
amount), wrong route of administration , or wrong subject . 
The medication error category must be recorded on the AE form in the eCRF. In addition , AEs 
originating from a medication error must be recorded as separate events . If an AE originating 
from the medication error qualifies as an SAE, expedited reporting is required ( Section 13.4). 
If the medication error is due to a device deficiency , the device deficiency  must be reported as 
a product complaint as described in Section  9.10. 
13.6.4  Misuse  
Misuse refers to situations where the IMP is intentionally and inappropriately used not in 
accordance with the protocol.  
The term ‘misuse ’ must be recorded on the AE form in the eCRF. In addition AEs originating 
from misuse must be recorded as separate events . If an AE originating from misuse qualifies 
as an SAE, expedited reporting is required ( Section 13.4). 
13.6.5  Abuse  
Abuse relates to the sporadic or persistent, intentional excessive use of an IMP which is 
accompanied by [CONTACT_3584].  
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 80 of 123 
The term ‘abuse ’ must be recorded on the AE form in the eCRF. In addition, AEs originating 
from abuse must be recorded as separate events . If the AE originating from abuse qualifies as 
an SAE, expedited reporting is required (Section 13.4). 
13.6.6  Aggravation of condition  
Any clinically significant aggravation/exacerbation/worsening of any medical condition(s), 
compared to screening , must be reported as an AE  in accordance with Section  13.3. If the AE 
originating from aggravation of condition qualifies as an SAE, expedited reporting is required 
(Section  13.4). 
13.7 Follow -up for final outcome of adverse events  
During the trial , the investigator should follow up for final outcome on all AEs (including 
SAEs). Once a subject leaves the clinical trial, the investigator should follow up on the 
outcome of all non -serious AEs classified as of possible/probable relationship to the IMP for 
[ADDRESS_621544] stabilised and cannot be expected to 
recover during study or safety follow -up periods, for example chronic illnesses, the final 
outcome shoul d be reported as ‘not recovered ’. In addition, a statement that the SAE has 
stabilised or is chronic should be added to the narrative description of the SAE on the SAE 
form.  
13.8 Handling of an urgent safety measure  
An urgent safety measure is a measure taken t o implement an action/protocol deviation under 
an emergency. This is defined as “…the occurrence of any new event relating to the conduct 
of the trial or the development of the investigational medicinal product where that new event 
is likely to affect the safety of the subjects, the sponsor and the investigator shall take 
appropriate urgent safety measures to protect the subjects against any immediate 
hazard. ” (35). 
If the investigator becomes aware of information that necessitates an immediate change in th e 
clinical trial procedure or a temporary halt to the clinical trial in order to protect clini cal trial 
subjects from any immediate hazard to their health and safety, the investigator can do so 
without prior approva l from LEO, regulatory authorities , or IRBs . 
The investigator must immediately inform LEO – by [CONTACT_483635] – of this change in the clinical trial procedure or of the temporary halt 
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.[ADDRESS_621545] immediately upon receipt of the urgent safety measure notification in 
accordance with internal procedures  and local legislation . 
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 82 of 123 
14 Statistical m ethods  
14.1 Sample size 
A total of 200  subjects will be randomis ed 1:[ADDRESS_621546] s in the FAS and 160  subjects anticipated in the per protocol set , the trial will 
provide 98% power to establish non -inferiority with regard to positive anti -tetanus response 
based on a one-sided significance level of 2.5%, assuming a response rate of 80 % in both 
arms and a non -inferiority margin of -25%. Assuming a positive anti-meningococcal response 
rate of  80% in both arms , an IGA 0/1 response rate of 30% (tralokinumab) versus 10% 
(placebo), and an EASI75 response rate of 40% (tralokinumab) versus 15% (placebo) , the 
trial will provide approximately 89% power for rejecting al l 4 hypotheses related to the 
primary and secondary endpoints  with each hypothesis  tested at a one -sided 2.5% significance 
level . This evaluation is assuming no correlation between the primary and secondary 
endpoints.  
To our knowledge there is no established margin in the literature for showing non -inferiority 
with regard to immune responses to vaccines and the s ample size of previously conducted 
trials with similar objective varies. In a similar type of trial with dupi[INVESTIGATOR_483584] -to-severe atopic dermatitis (36), a total of 194  subjects was randomised 
(1:1) to ass ess vaccine response but no non -inferiority margin was pre -specified. By [CONTACT_22242], 
in a trial with ixekizumab versus placebo in healthy subjects, a total of 84  subjects were 
randomised (1:1) and a non -inferiority margin of -40% was pre -specified ( ClinicalTrial s.gov 
[STUDY_ID_REMOVED]) . Similarly, a non -inferiority margin of -40% was pre -specified in a trial with 
secukinumab versus placebo in healthy subjects (37). 
On the basis of knowledge from previous trials, the proposed sample size and non -inferiority 
margin of -25% is considered appropriate to assess the primary objective of the trial .  
14.2 Trial analysis sets 
All screened subjects will be accounted for in the CTR.  
All subjects randomised to treatment are included in the FAS and will be analy sed for efficacy 
up to Week  16. Exclusions from the FAS can be considered in special cases  as described in 
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.[ADDRESS_621547] from 
the FAS, a justification addressing ICH E9 will be given.  
A per protocol analysis set will be defined by [CONTACT_483636]:  
Receive no treatment with the IMP (vaccines).
Provide no vaccine data at Week 16.
Are known to have taken the wrong IMP throughout the treatment period.
Do not fulfil the inclusion criteri a no.  3, 6, 7, 8.
Meet exclusion criterion related to receipt of other vaccines ( that is, exclusion
criterion no.  10).
Initiate systemic rescue treatment prior to Week  10 and who are still treated
with or exposed to systemic rescue treatment at Week  10 (that is, Week  10
[visit  8] occurs within [ADDRESS_621548] dose of systemic rescue
medication).
Initiate systemic rescue treatment at Week  10 or later.
Have missed more t han 2  doses of tralokinumab/placebo before vaccine
administration.
Have missed any of the last 2  doses of tralokinumab/placebo before vaccine
administration (that is, Weeks  8 and 10).
The per protocol analysis set will be used as primary analysis set for the vaccine antibody 
responses at Week  16 (primary endpoints; Panel 13). For the secondary endpo ints (IGA 0/1 
and EASI75 at Week  16), the FAS  analysis will be considered primary . 
A safety analysis set will be defined by [CONTACT_483637].  
Based on the above -mentioned rules, the inclusion/exclusion of subjects or subject data from 
the trial analysis sets will be documented in the statistical analysis plan update before 
breaking the randomisation code.  
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 84 of 123 
14.3 Statistical analysis  
14.3.1  Disposition of subjects 
For all randomised subjects the reasons for permanent discontinuation of IMP and for leaving  
the trial will be presented by [CONTACT_1570].  
14.3.2  Demographics and other baseline characteristics  
Descriptive statistics of demographics and other baseline cha racteristics will be presented f or 
all randomised subjects  and the per protocol analysis set . The presentations will be overall  and 
by [CONTACT_1570]. Presentation s of age, sex, ethnicity, and race will also be given by  
[CONTACT_22789] (IGA 3 or  4). 
Demographics include age, sex, race, and ethnicity. Other baseline characteristics include v ital 
signs (including height, weight, body mass index), duration of AD, concurrent diagnoses 
(from medical history and indications for concomitant medication), conc omitant medication, 
and previous AD treatments.  
14.3.3  Exposure and treatment compliance  
Exposure to treatment will be presented for the safety analysis set as days of exposure per 
treatment group.  
Adherence to treatment regimen will be recorded in the eCRF. If any complications or 
deviations in administration are observed, these will be described as protocol deviations. 
Adherence will be presented for the safety analysis set for each treatment group.   
14.3.4  Multiple t esting procedure  
The primary and secondary endpoint s will be evaluated hierarchically in the order  shown in 
Panel 13. 
The hypothesis relating to a specific endpoint cannot be rejected unless all hypotheses rela ting 
to endpoints earlier in the hierarchy are also rejected .  
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 85 of 123 
Panel 13: Testing procedure for primary and secondary endpoints  
EASI, Eczema Area and Severity Index; EASI75, at least 75% reduction in EASI score; IGA, Investigator’s 
Global  Assess ment . 
Non-inferiority hypothesis to be tested for the primary endpoints:  H0: tralo-placebo   -25% 
versus H1:tralo -placebo > -25%,  
Superiority hypothesis to be tested for the secondary endpoints:  H0: tralo-placebo   0% v ersus 
H1:tralo -placebo > 0%,   
where tralo and placebo  denotes the response rate with tralokinumab and placebo, respectively. 
All hyp otheses will be tested at a one -sided 2.5% significance level. For the non -inferiority 
hypotheses, the null hypothesis will be rejected if the two -sided 95% CI for the difference in 
immune response rate lies entirely to the right of the non -inferiority limit ( -25%). For the 
superiority hypotheses, a two -sided 95% CI for the difference in response rates and a 
corresponding two -sided p -value  will be calculated ; the null hypothesis will be rejected if the 
p-value is smaller than 5% and the point estimate is in favour of the alternative hypothesis
(that is, greater than 0).  
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 86 of 123 
14.3.5  Analysis of primary endpoint s 
Positive anti -tetanus response at Week  16 (3-fold IgG increase compared to Week  12 if 
IgG ≤1.0 IU/mL at Week  12; or IgG  ≥2.5 IU/mL if IgG  >1.0 IU/mL at Week  12) and positive 
anti-meningococcal response at Week  16 (IgG ≥3.0 mcg/mL with at least a 3 -fold increase 
compared to Week 12 ) are binary end points. The difference in response rates between 
treatment groups will be calculated using the Mantel -Haenszel  estimate of the risk difference  
stratified by [CONTACT_22789] (IGA 3 or 4) together with the 95%  CI. Non-inferiority  
of tralokinumab wi ll be demonstrated if the lower limit of the 95%  CI is greater than -25%.  
The primary endpoints will be analysed for FAS and the per protocol set ; the per protocol 
analysis will be considered the primary  analysis . Analyses  will be based on observed data; 
hence,  missing data will not be imputed.  
14.3.6  Analysis of secondary endpoints  
[IP_ADDRESS]  Overview of estimand framework  
Three estimands addressing different aspects of the trial objectives will be defined:  
Primary estimand: ‘composite ’.
Secondary estimand: ‘hypothetical ’.
Tertiary estimand: ‘treatment policy ’.
The applied estimands incorporate 2 main types of events that influence how the treatment 
effects are estimated:  
Initiation of rescue medication : Some of the estimands use the initiat ion of rescue
medication as an event that modifies the applied value of an endpoint, e.g. by [CONTACT_331860] a
subject receiving rescue medication as a non -responder.
Permanent discontinuation of IMP : This event occurs when a subject is permanently
withdrawn from  the treatment or the trial as described in Section  10.3. This can either
happen at his/her own initiative or at the investigator ’s discretion. The event also includes
the possibility of a subject being lost to follow -up. The timing of the event is  defined as
the date of the early termination vi sit for withdrawn subjects or – in the case  of a subject
lost to follow -up – the date of the last known visit to the clinic. As for the rescue
medication, the event type is used to modify an applied endpoint value.
All analyses will be based on the FAS unless otherwise specified.  
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 87 of 123 
[IP_ADDRESS]  Primary estimand: ‘composite ’ 
The primary estimand for the first 2 secondary endpoints will be:  
Treatment difference in response rates of IGA 0/1 and EASI75 after 16 weeks
achieved w ithout rescue medication, regardless of treatment discontinuation.
The primary estimand assesses the expected difference in response rates (defined as response  
obtained without initiation of any rescue med ication) after [ADDRESS_621549] 
received rescue medication will be considered non -responders, reflecting an assumption that 
initiation of rescue medication indicates failure of the randomised treatment to achieve 
response, and that a  (possible) observed positive response after initiation of rescue medica tion 
is not attributable to the randomised treatment. Missing data for subjects who did not atten d 
the Week  [ADDRESS_621550] stratified by [CONTACT_22789] (IGA  3 or 4). The 
treatment estimate and the corresponding 95%  CI wil l be presented. The null hypothesis of no  
difference in response rates between tralokinumab and placebo will be tested against the 
2-sided alternative that there is a difference.
Sensitivity analyses for the primary estimand  
Two sensitivity analyses are s pecified for the primary estimand. In both cases the same 
Cochran -Mantel -Haenszel test as used for the primary analysis will be applied including 
stratification by [CONTACT_22789].  
The purpose of the analyses is to assess the robustness of results of the primary analysis wi th 
respect to the retrieved data at Week  16 and assumptions regarding missing Week  16 data.  
Sensitivity analysis 1 : All subjects who have permanently discontinued IMP prio r to Week  [ADDRESS_621551] discontinued treatment.  
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 88 of 123 
Sensitivity analysis 2 : Rather than imputi ng all subj ects who do not attend the Week  [ADDRESS_621552] value is a more reliable estimate of the missing response (tha n a 
non-response).  
Supplementary analysis  
The primary analysis of the primary estimand is repe ated based on the per protocol analysis 
set. 
[IP_ADDRESS]  Secondary estimand: ‘hypothetical ’ 
The secondary estimand for the first 2 secondary endpoints will be:  
Treatment difference in response rates  of IGA 0/1 and EASI75 after 16  weeks
if all subjects adhered to the t reatment regimen in the sense that they did not
discontinue IMP permanently and no rescue medication  was made available
before Week  16.
The secondary estimand assesses the expected difference in response rates achieved when 
adhering to the treatment regim en tralokinumab with no rescue medication as compared to a 
treatment regimen with placebo with no rescue medication.  
Primary analysis of the secondary estimand  
Data collected after permanent discontinuation of IMP or after initiation of rescue medicati on 
will not be applied in the analysis.  
IGA 0/1 responder imputation  
Imputation of missing binary IGA 0/1 data at Week  16 will be done using multiple 
imputations of the underlying 5 -point IGA values within the 2  groups defined according to 
randomised treatm ent arm assuming that data is missing at random within each arm.  
1.In each group, intermittent missing values will be imputed using LOCF to obtain a
monotone missing data pattern.
2.An ordinal logistic regression model assuming proportional odds will be fitted  to the
IGA value at Week 2. The model will include baseline disease severity (IGA  3 or 4) as
factor. The estimated parameters, and their variances, will be used to impute missing
IGA values at Week 2. 100 copi[INVESTIGATOR_215520] (seed=1382 7641 ).
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.[ADDRESS_621553] as for Week 2. The imputations will be based on a proportional odds
logistic regression model with effects of baseline disease severity (IGA  3 or 4)
together with the IGA value at Week  2 as factors. The estimated parameters, and their
variances, will be used to impute missing values at Week  4.
4.This stepwise procedure will then be repeated sequentially for Week 6, 8, 10, 12, 14,
and 16 with the modifi cation that only the IGA values from the 2 preceding visits will
be included as factors in addition to baseline disease severity. The missing binary IG A 
0/1 response at Week  16 will be derived from the corresponding underlying imputed
IGA value.
EASI75 res ponder imputation  
Imputation of mis sing binary EASI75 data at Week  16 will be done using multiple 
imputations of the und erlying 72 -point EASI values within the 2 groups defined according to 
randomised treatment arm assuming that data is missing at random w ithin each arm.  
1.Intermittent missing values will be imputed in each group using a Markov Chain
Monte Carlo method to obtain a monotone missing data pattern and 100  copi[INVESTIGATOR_483585] (seed=456249 41).
2.An ANCOVA model is fitted to the EASI value at Week  2. The model will include
effects of baseline EASI as a covariate, and baseline disease severity (IGA  3 or 4)  as a
factor . The estimated parameters, and their variances, will be used to impute missing
EASI values at Week  2. 100  copi[INVESTIGATOR_483586] (seed=111099 41).
3.For each of the [ADDRESS_621554] as for Week  2. The imputations will be based on the same
ANCOV A model with effects of baseline EASI as  a covariate, and baseline disease
severity (IGA 3 or 4) as a factor  together with the EASI value at Week  2 as covariate.
The estimated parameters, and their variances, will be used to impute missing values
at Week  4.
4.This stepwise procedure will then be repeated sequentially for Week 6, 8, 10, 12, 14,
and 16 with the modification that only the EASI values from the preceding 2 visits
will be included as covariates in addition to baseli ne EASI as a covariate and baseline
disease severity as a factor . The mi ssing binary EASI75 response at Week  16 will be
derived from the corresponding underlying imputed EASI value.
Analysis of Week 16 response  
For each of the 100  complete data sets, the difference in response rates (either the IGA 0/1 or 
the EASI75) between t reatment groups wil l be analysed using the Cochran -Mantel -Haenszel 
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.[ADDRESS_621555] stratified by [CONTACT_22789] (IGA 3 or 4). The estimates a nd standard errors 
from the [ADDRESS_621556] error using Rubin ’s rule to draw inference. From these pooled estimates, the 95%  CI 
for the treatment difference will be calculated.  
Sensitivity analysis for the secondary estimand  
Rather than assuming that observations are missing at random within each treatment arm, it i s 
assumed that missing data from subjects who discontinue IMP permanently/receive rescue 
medication in the tralokinumab arm will resemble missing data from subjects  from the 
placebo arm who do not discontinue IMP permanently/receive rescue medication. The 
underlying assumption is that the effect of tralokinumab following rescue medication or 
permanent treatment discontinuation is similar to the effect of placebo. It should be noticed  
that this assumption is pronouncedly conservative in favour of placebo as it tends to minimi se 
the differences between arms.  
Imputation of missing data at Week  16 will be done using a pattern mixture model where 
missing data in the tralo kinumab arm as well as the placebo arm will be imputed from 
observed data in the placebo arm (using a so -called copy -reference approach). With this 
exemption, the stepwise multiple imputation procedure and subsequent analysis will be 
conducted in the same way as specified for the primary analysis of the secondary estimand.  
[IP_ADDRESS]  Tertiary estimand: ‘treatment policy ’ 
The tertiary estimand for the first 2 secondary  endpoints will be:  
Treatment difference in response rate after [ADDRESS_621557] 
permanently discontinued IMP prior to Week  16. Within a given treatment arm, retrieved data 
from discontinued subjects will be used to impute missing data for other discontinued 
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.[ADDRESS_621558] as specified for the primary analysis of the secondary estimand.  
For discontinued subjects, it is expected that the number of subjects with retrieved data at  
Week  16 will be too small to facilitate the same imputation model as mentioned above. 
Consequently, an imputation model with only baseline effects (IGA as a factor and EASI as a 
covariate [only for EASI75]) will be applied for discontinued subjects. Some factor s may 
have to be omitted, depending on the observed data, e.g. if retrieved subjects all have the 
same baseline severity.  
The imputed datasets will be analysed in the same way as specified for the primary analysis of 
the secondary estimand.  
Sensitivity ana lyses for the tertiary estimand  
Rather than imputing Week  [ADDRESS_621559] -Roger approximation to 
estimate denominator degrees of freedom, and the mean modelled as follows (shown for 
change from baseline in SCORAD):  
Change from baseline in SCORAD  
= treatment × visit + baseline SCORAD × visit + baseline IGA  
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 92 of 123 
This model assumes that data is missing at random within each treatment arm. The estimates 
will be presented with nominal p -values and 95%  CI at each visit. Data collected a fter 
permanent discontinuation of IMP or after initiation of rescue medication will not be includ ed 
in the analysis. All analyses will be based on the FAS.  
14.3.8  Analysis of safety  
The analyses of safety will be based on the safety analysis sets.  
[IP_ADDRESS]  Adverse events  
AEs will be coded during the course of the trial according to Medical Dictionary for 
Regulatory Activities (MedDRA). AEs will be presented by [CONTACT_121606] (SOC).  
Treatment -emergent AEs will be summarised, however, all AEs recorded during the course of 
the trial will be included in the subject data listings. An event will be considered 
treatment -emergent if started after the first use of IMP or if started before the first use of IMP 
(applicable if subject had a wash -out) and  worsened in severity thereafter. The tabulations 
described in the following will only include the treatment -emergent events. In each of the 
tabulations, AEs will be defined by [CONTACT_421488].  
An overall summary of the number of treatment -emergent AEs, number (percentage) of 
subjects with any treatment -emergent AEs, SAEs, deaths, premature discontinuations from the 
trial due to AEs, treatment -related AEs and severe AEs will be presented.  
The number of AEs and the number of subject s experiencing each type of AE will be 
tabulated by [CONTACT_1570]. The percentage of subjects with AEs will be compared be tween 
treatment groups by a chi -square test or Fisher ’s exact test (if expected cell count < 5).  
The severity for each type of AE wi ll be tabulated by [CONTACT_1570]. 
The causal relationship to IMP (tralokinumab/placebo) for each type of AE will be tabulated 
by [CONTACT_1570]. Related AEs are defined as AEs for which the investigator has not 
described the causal relationship to IMP as ‘not related ’. The number of related AEs and the 
number of subjects experiencing each type of related AE will be tabulated. The percentage of  
subjects with related AEs will be compared be tween treatment groups by a chi -square test or 
Fisher ’s exact test  (if expected cell count < 5). 
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 93 of 123 
The causal relationship to IMP (each vaccine) for each type of AE will be tabulated by 
[CONTACT_1570]. Related AEs are defined as AEs for which the investigator has not described  
the causal relationship to IMP as ‘not related ’. The number of related AEs and the number of  
subjects experiencing each type of related AE will be tabulated. The percentage of subjects 
with related AEs will be compared be tween treatment groups by a chi -square test or Fisher ’s 
exact test (if expected c ell count <5).  
SAEs and AESIs will be evaluated separately and a narrative for each will be given. AEs 
leading to withdrawal from trial will be listed.  
[IP_ADDRESS]  Vital signs 
The change in vital signs (blood pressure, heart rate, body temperature) from baseline to each 
visit will be summarised by [CONTACT_421490], standard deviation, median, 
minimum and maximum values for the safety analysis set . 
[IP_ADDRESS]  Clinical laboratory evaluation  
The change in each of the laboratory parameters from baseline to each vis it will be 
summarised by [CONTACT_421490], standard deviation, median, minimum and 
maximum values for the safety analysis set . 
Laboratory parameters will be classified as ‘low’, ‘normal ’ or ‘high’, depending on whether 
the value is below, within or above the reference range, respectively. A shift table will be 
produced showing the categories at baseline against those at end of treatment. Subjects with  
laboratory parameters outside the reference range will be listed.  
[IP_ADDRESS]  Pharmacokinetics  
 All th e PK samples in the trial are trough samples. The C trough concentration will be listed b y 
treatment group and descriptive statistics will be provided.  
Ctrough values from subjects with positive ADA/nAb will be compared to values from subject 
with negative ADA/nAb if data permits.  
The PK data will be merged with those from other clinical trials with tralokinumab for a 
population -based meta -analysis. Results of the meta -analysis will be presented in a separate 
pharmacometrics report outside of the CTR.  
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 94 of 123 
[IP_ADDRESS]  Anti -drug antibodies 
ADA status (positive versus negative) at each visit will be summarised by [CONTACT_1570]. I f 
considered relevant, descriptive statistics including number of subjects, mean, standard 
deviation, median, and range of the actual ADA titres by [CONTACT_73341]. The ADA status across the trial for each subject (positive versus negative) will a lso 
be classified and summarised by [CONTACT_1570].  
The association of ADA status across the trial (positive  versus  negative) with AEs/SAEs may 
be evaluated. In addition, the association of ADA titres (≥ median titre in positive subject s 
versus <  median titre) with AE/SAEs may be evaluated for ADA -positive treated subjects 
only. The ADA -positive subjects across the trial may also be divided into p ersistent positiv e 
versus transient positive. A subject will be considered as persistent positive if he/she has  
positive ADA for at least [ADDRESS_621560] 
will be considered as transient ADA positive. The ass ociations between ADA and AE/SAEs 
may be summarised for both persistent positive subjects versus transient positives subjects.   
For subjects who develop ADA, the IGA score and change in EASI at end of treatment will be 
listed.  
Evaluations of nAB will be c onducted on those serum samples that test positive for ADA. The 
test sample is deemed positive or negative for the presence of nAb to tralokinumab relative to 
a pre -determined (in assay validation), statistically derived cut point.  
For ADA, all subjects w ith titre information will be listed.  
14.3.9  Interim analysis  
No interim analysis is planned.  
14.3.10  General principles  
All hyp otheses will be tested at a one-sided 2.5% significance level. This will be done by 
[CONTACT_483638] -sided 95% CIs and p -value (note that fo r the non -inferiority hypotheses a 
different approach will be used).  
An observed -cases approach will be used for tabulations of data by [CONTACT_765] (i.e. , involving on ly 
those subjects who attended each specific visit).  
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.[ADDRESS_621561] deviation, minimum and maximum values.  
All the analyses specified in the protocol will be reviewed in relation t o the blinded data 
actually obtained and the statistical analysis plan update will be finalised before breaking  the 
randomisation code.  
Any changes from the statistical analysis planned in this clinical trial protocol will be 
described and justified in a p rotocol amendment, the statistical analysis plan update and/or  in 
the CTR dependent on the type of deviation.  
14.3.11  Handling of missing values  
Procedures for handling of missing values are included under the sections describing the 
individual analyses.  
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 96 of 123 
15 Refere nces 
1.Silverberg JI, Hanifin JM. Adult eczema prevalence and associations with asthma and
other health and demographic factors: a US population -based study. J Allergy Clin
Immunol. 2013;132(5):[ADDRESS_621562] Wor king Group. A population
based survey of eczema prevalence in the [LOCATION_002]. Dermatitis. 2007;18(2):82 -91.
3.Bieber T. Atopic dermatitis. N Engl J Med. 2008;358(14):1483 -1494.
4.Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387([ZIP_CODE])1109 -1122.
5.Kiebert G, Sorensen SV , Revicki D, Fagan SC, Doyle JJ, Cohen J, et al. Atopic dermatitis
is associated with a decrement in health -related quality of life. Int J Dermatol.
2002;41(3):151 -158.
6.Tazawa T, Sugiura H, Sugiura Y , Uehara M. Relative importance of IL-4 and IL -13 in
lesional skin of atopic dermatitis. Arch Dermatol Res. 2004;295(11):[ADDRESS_621563] Dermatol. 2014;134(5):1342 -1350.
8.Aleksza M, Lukács A, Antal -Szalmás P, Hunyadi J, Szegedi A. Increased frequency of
intracellular interleukin (IL) -13 and IL -10, but not IL -4, expressing CD4+ and CD8+
peripheral T cells of patients with atopic dermatitis. Br J Dermatol. 2002;147(6):[ADDRESS_621564] CD4+CCR4+ T cells: possible role in atopic dermatitis. J Invest Dermatol.
2006;126(5):1043 -1051.
10.Oh MH, Oh SY , Lu J, Lou H, Myers AC, Zhu Z, Zheng T. TRPAA1 -dependent pruritus in
IL-13-induced chronic atopic dermatitis. J Immunol. 2013;191(11):[ADDRESS_621565]
Dermatol. 2009;129:742 -751.
12.Simpson EL, Bieber T, Guttman -Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two
phase 3 trials of dupi[INVESTIGATOR_110972]. N Engl J M ed. 2016 Dec
15;375(24):2335 -2348.
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.[ADDRESS_621566], Monk PD, Cohen ES, Manuel D, Dempsey F, Davis NH, et al. Preclinical
development of CAT -354, an IL -13 neutralizing antibody, for the treatment of severe
uncontrolled asthma. Br J Pharmacol. 2012;166(1):[ADDRESS_621567]
interleukin -13, using ribosome display. Methods Mol Biol. 2012;805:[ADDRESS_621568] C, Mishra A, Saito -Akei H, Monk P, Anderson I, Rothenberg ME. Inhibition of
human interle ukin-13-induced respi[INVESTIGATOR_238594] -human
interleukin -13 antibody (CAT -354). Clin Exp Allergy. 2005;35(8):1096 -1103.
16.Hershey GK. IL -13 receptors and signaling pathways: an evolving web. J Allergy Clin
Immunol. 2003;111(4):677 -690.
17.Nomura I, Goleva E, Howell MD, Hamid QA, Ong PY , Hall CF, et al. Cytokine milieu of
atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune
response genes. J Immunol. 2003;171(6):3262 -3269.
18.Looney RJ, Diamond B, Holers VM,  Levesque M, Moreland L, Nahm M, et al.
Guidelines for assessing immunocompetency in clinical trials for autoimmune diseases.
Clin Immunol. 2007;123(3):235 -243.
19.Moffat GJ, Davies R, Kwon G, Retter MW, Chellman GJ, Kanapuram S, et al.
Investigation of mater nal and fetal exposure to an IgG2 monoclonal antibody following
biweekly intravaginal administration to cynomolgus monkeys throughout pregnancy.
Reprod Toxicol. 2014;48:132 -137.
20.Bancroft AJ, Artis D, Donaldson DD, Sypek JP, Grencis RK. Gastrointestinal nem atode
expulsion in IL -4 knockout mice is IL -13 dependent.
Eur J Immunol.  2000;30(7):2083 -2091.
21.Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol.
1980;92(Suppl):44 -47.
22.Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 20 10 statement:
updated guidelines for reporting parallel group randomised trials. BMC Med. 2010;8:18.
23.Johansson SGO, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, et al. Revised
nomenclature for allergy for global use: report of the Nomenclature Rev iew Committee of
the World Allergy Organization, October 2003.
J Allergy  Clin Immunol.  2004;113(5):832 -836.
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 98 of 123 
24.Sampson HA, Muñoz -Furlong A, Campbell RL, Adkinson FN Jr, Bock SA, Branum A, et
al. Second symposium on the definition and management of anaphylaxis: Summary
report  - Second National Institute of Allergy and Infectious Diseases/Food Allergy and
Anaphylaxis Network symposium. J Allergy Clin Immunol. 2006;117(2):391 -397.
25.Posner K, Oquendo MA, Gould M, Stanley B, Davies M. Columbia Classification
Algorithm of Suicide Assessment (C -CASA): classification of suicidal events in the
FDA ’s pediatric suicidal risk analysis of antidepressants. Am J Psychiatry. 2007;
164(7):1035 -1043.
26.Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Grae ber M.  The eczema area and
severity index (EASI): assessment of reliab ility in atopic dermatitis.
Exp Dermatol . 2001; 10(1): 11-18.
27.Harmonising Outcome Measures for Eczema (HOME). EASI scoring table for aged 8 and
over [homepage on the Internet]. Available f rom:
http://www.nottingham.ac.uk/homeforeczema/index.aspx  [cited  21-Nov-2016].
28.European Task Force on Atopic Dermatitis . Severity scoring of atopic dermatitis: the
SCORAD index. Consensus report of the European task force on atopic dermatitis.
Dermatology . 1993;186(1):23 -31.
29.Finlay AY , Khan GK. Dermatology Life Quality Index (DLQI) – a simple practical
measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210 -216.
30.Greiner W, Weijnen T, Nieuwenhuizen M, Oppe S, Badia X, Busschbach J, et al. A single
European currency for EQ -5D health states. Results from a six -country study. Eur J Health
Econ. 2003;4(3):222 -231.
31.Charman CR, Venn AJ, Williams HC. The patient -oriented eczema measure: development
and initial validation of a new tool for measuring atopic eczema severity from the patients ’ 
perspective. Arch Dermatol. 2004;140(12):1513 -1519.
32.Zigmond A S, Snaith RP. The hospi[INVESTIGATOR_56105]. Acta Psychiatr Scand.
1983;67(6):361 -370.
33.Menactra® Meningococcal (Groups A, C, Y and W -135) Pol ysaccharide Diphtheria
Toxoid Conjugate Vaccine [package insert]. Swiftwater, Pennsylvania , US: [COMPANY_011]
Pasteur,  Inc. 2017 [ version 0.18 dated 16 -Sep-2016 ; cited 14 -Feb-2018 ]. Available from
the US FDA ’s website.
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 99 of 123 
34.Boostrix® (Tetanus Toxoid, Reduced Diphtheri a Toxoid and Acellular Pertussis Vaccine,
Adsorbed) . [package insert].  Research Triangel Park, North Carolina: GlaxoSmithKline
[cited 14-Feb-2018]. Available from  the US FDA ’s website.
35.European Parliament and Council of The European Union. Directive 2001/20/EC of
[ADDRESS_621569] of clinical trials on medicinal products for hu man use [2001 ], article  10.
36.Blauvelt A, Simpson E, Wu R, Akinlade B, Graham N, Pi[INVESTIGATOR_125415] G, et al. The effect of
dupi[INVESTIGATOR_483587] -to-severe atopic
dermatitis; a randomized, double -blind, placebo -controlled trial. Allergy.
2016;71(Suppl.102):95.  DOI: 10.1111/all.[ZIP_CODE] .
37.Chioato A, Noseda E, Stevens M, Gaitatzis N, Kleinschmidt A, Pi[INVESTIGATOR_441813] H.  Treatment with
the interleukin -17A-blocking antibody secukinumab does not interfere with the efficacy of
influenza and meningococcal vaccina tions in healthy subjects: results of an open -label,
parallel -group, randomized single -center study.
Clin Vaccine  Immunol.  2012;19(10):1597 -1602.
38.World Medical Association 2013. Declaration of Helsinki  – ethical principles for medical
research involving hu man subjects.  7th (Fortaleza) amendment.
39.International Ethical Guidelines for Health -related Research Involving Humans, Fourth
Edition. Geneva. Council for International Organizations of Medical Sciences (CIOMS);
2016.
40.International Council for Harmonisation of Technical Requirements for Pharmaceuticals
for Human Use (ICH)  2016. Integrated addendum to ICH E6(R1): Guideline for good
clinical practice E6(R2) .
41.World Health Organization. WHO model prescribing information: drugs used in skin
diseases . Geneva. 1997 .
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 100 of 123 
Appendix 1: Definitions of adverse events and serious adverse events  
Adverse event definition  
An AE is defined as any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product and which does not necessarily have a causal 
relationship with this treatment. An AE can therefore be any unfavourable and u nintended 
sign (including an abnormal laboratory finding), symptom, or disease temporally associated 
with the use of a medicinal (investigational) product, whether or not related to the medicinal 
(investigational) product.  (ICH Harmonized Tripartite Guidel ine for Good Clinical Practice, 
E6 (R1)).  
This definition includes:  
Accidental injuries.
Events related to trial procedures.
Reasons for any unfavourable and unplanned change in  medication (drug
and/or dose).
Clinically significant worsening  of pre -existin g conditions.
Reasons for admission to hospi[INVESTIGATOR_483588] .
AEs commonly observed and AEs anticipated based on the pharmacological
effect of the IMP.
Any laboratory abnormality assessed as clinically significant by [CONTACT_31035] (see Section  11.4.5 ).
Serious a dverse event definition  
An SAE is any untoward medical occurrence that 
Results in death .
Is life -threatening .
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 101 of 123 
Requires inpatient hospi[INVESTIGATOR_15574].
Planned hospi[INVESTIGATOR_483589] ’s medical
record.
Results in persistent or significant disability/incapacity .
Is a congenital anomaly/birth defect .
or 
Is a medically important condition. Events that may not be immediately
life-threatening or result in death or hospi[INVESTIGATOR_483590]. Examples are intensive treatment in an emergency
room or at home for allergic broncospasm , blood dyscrasias and convulsions
that do not result in hospi[INVESTIGATOR_11956] , development of drug dependency or drug
abuse.
Adverse events of special interest are described in Section  13.6.1 . 
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 102 of 123 
Appendix 2: Classification of adverse events  
Severity  
The severity  of the AE should  be described in terms of mild, moderate or severe according to 
the investigator ’s clinical judgement.  
Mild  An AE that is usually transient and may require only minimal treatment or 
therapeutic intervention. The event does not generally interfere with usual 
activities of daily living.  
Moderate  An AE that is usually alleviated with additional specific therapeutic 
intervention. The event interferes with usual activities of daily living, 
causing discomfort but poses no significant or permanent risk of harm to the 
subject.  
Severe  An AE that interrupts usual activities of daily living, or significantly affec ts 
clinical s tatus, or may require intensive therapeutic intervention.  
If the severity of an AE worsens, a new AE should be recorded.  
Causality  
The causal relation  of the AE to the use of the IMP (tralokinumab/placebo) should  be 
described in terms of probable, possible , or not related according to the investigator ’s clinical 
judgement. The categories are defined below.  Similarly, the causal relationship to each of the 
vaccines should be evaluated using the  categories defined below (that is, probably related, 
possibly related, or not related).  
Probably 
related  Follows a reasonable temporal sequence from administration of the IMP. 
Could not be reasonably explained by [CONTACT_423] ’s clinical state, 
environmental or toxic factors o r other therapi[INVESTIGATOR_73258] . 
Follows a known pattern of response to the IMP. 
Disappears or decreases on cessation or reduction in dose of the IMP. 
Reappears or worsens upon re -challenge . 
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.[ADDRESS_621570] ’s clinical state, 
environmental or toxic factors or other therapi[INVESTIGATOR_73258] . 
Follows a known pattern of response to the IMP. 
Not related  Does not follow a reasonable temporal sequence from administration of the 
IMP. 
Is better explained by [CONTACT_73343] ’s clinical state, 
environmental or toxic factors or other th erapi[INVESTIGATOR_73258] . 
Does not reappear or worsen upon re -challenge . 
Does not follow a known pattern of response to the IMP. 
Outcome  
The outcome  of the ev ent according to the investigator ’s clinical judgement should  be 
classified  using the categories below.  
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 104 of 123 
Recovered/  
resolved  The event has stopped. The stop date of the event must be recorded.  
Recovering/  
resolving  The subject is clearly recovering from an event. The event is not yet 
completely resolved.  
Not 
recovered/  
not resolved  Event is still ongoing. 
Recovered /   
resolved  with 
sequelae  The event has reached a state where no further changes are expected and the 
residual symptoms are assumed to persist. An example is hemiparesis after 
stroke.  
The stop date of the event  must be recorded. In case of a SAE, the sequelae 
should be specified.  
Fatal  The subject has died as a consequence of the event. Date of death is recorded 
as stop date for the AE.  
Unknown  Unknown to investigator, e.g. subject lost to follow -up. 
Note that as per the above definition, LEO uses “recovered/resolved ” only if an event has 
actually stopped. According to the CDISC definition, the category “recovered/resolved ” also 
includes events which have improved. However, following the LEO definitions above, such 
an improved event will instead be classified as “not recovered/not resolved ” or 
“recovering/resolving ”. 
Similarly, it should be noted that as per the above definition, LEO uses “recovered/resolved 
with sequelae ” only if an event has reached a s tate where the residual symptoms are assumed 
to persist. According to CDISC, an event is considered “with sequelae ”, if it has “retained 
pathological conditions ”. Consequently, it is likely that some of the events classified by [CONTACT_483639] “recove red/resolved with sequelae ” could have been classified with the 
outcome “recovered/resolved ” according to the CDISC definition.  
For SAEs which have stabilised and cannot be expected to recover during study or safety 
follow -up periods, for example chronic i llnesses, the final outcome should be reported as ‘not 
recovered ’. In addition, a statement that the SAE has stabilised or is chronic should be added 
to the narrative description of the SAE on the SAE form.  
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 105 of 123 
Appendix  3: Trial  governance considerations  
Appendix 3 A: Regulatory and ethical considerations  
This trial will be conducted in accordance with the protocol and with the following:  
Consensus ethical principles derived from international guidelines including the
current versio n of the Declaration of Helsinki (38) and Council for International
Organizations of Medical Sciences (CIOMS) International Ethical Guidelines  (39).
Current version of a pplicable International Council for Harmonisation ( ICH) Good
Clinical Practice (GCP) Guidelines  (40).
EU’s General Data Protection Regulation 2016/679 of 27 April 2016 .
Applicable laws and regulations .
The appropriate regulatory authorities  must be notified of/approve the clinical trial as 
required.  
Any documents that  the IRB  may need to fulfil  its responsibilities (such as the trial protoc ol, 
protocol amendments, Investigator ’s Brochure, subject information leaflet, ICFs , or 
advertisements)  will be submitted to the IRB . These documents must be reviewed and 
approved by [CONTACT_483640] . 
Any amendments to the protocol must be approved by/receive favourable opi[INVESTIGATOR_483591] , as required , prior to implementation.  
The principal investigator [INVESTIGATOR_184729] , if required by [CONTACT_71882] : 
Providing written summaries of the status of the trial to the IRB  annually or more
frequently in accordance with the requirements, policies, and proce dures established
by [CONTACT_1201] .
Notifying the local IRB of SAEs or other significant safety  findings as required by
[CONTACT_166556] .
Providing oversight of the conduct of the trial at the trial site and adher ing to
applicable national and international legislation .
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 106 of 123 
Appendix 3B: Informed c onsent process  
Subjects will receive written and verbal information concerning the clinical trial. This 
information will emphasise that participation in the clinical trial is voluntary and that th e 
subject may withdraw from the clinical trial at any time and for any reason. All subjects wi ll 
be given an opportunity to ask questions and will be given suf ficient time to consider befor e 
consenting.  
The subject ’s signed and dated informed consent to participate in the clinical trial will be 
obtained prior to any clinical trial related procedure being carried out in accordance with ICH 
GCP (4.8) and all appli cable laws and regulations.  The authorised person obtaining the 
informed consent must also sign the ICF.  
Subjects  will be re -consented to the most current version of the ICF(s) during their 
participation in the trial, if required . 
A copy of the ICF(s) must  be provided to the subject . 
Subject card  
At screening, subjects will be provided with a card stating that they are participating in a  
clinical trial and which contains contact [CONTACT_49761](es) and telephone number(s) of relevant trial 
site staff, including the number for the investigator in case of emergency situations. The 
subject card also includes a local telephone number for the emergency unblinding CRO to be 
used if the investigator or delegated site staff cannot be reached or if unblinding in  the IRT 
cannot be performed.  
Appendix 3 C: Subject and data confidentiality  
This clinical trial protocol as well as all other information, data , and results relating to  this 
clinical trial and/or to the IMP  is confidential information of LEO and shall not be used by [CONTACT_483641].  
The investigator agrees that LEO may use any and all information, data , and results from this 
clinical trial in connection with the development of the IMPs  and, therefore, may disclose 
and/or transfer information, data and/or results to other investigators, regulatory authorit ies 
and/or commercial partners.  
Trial s ubjects will be assigned a unique identifier (subject  ID) by [CONTACT_82093] . Any subject ’s records 
or data sets that are transferred to LEO will contain the identifier only; subject names or any 
information which would make the subject identifiable will not be transferred.  
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.[ADDRESS_621571] be informed and consent to that their medical records may be examined by 
[CONTACT_483642] , by 
[CONTACT_61527], and by [CONTACT_6668].  
Processing of personal data 
This protocol specifies the personal data on trial subjects ( for example race, ethnicity, age, 
gender, health condition, medical history, test results, etc. ) which shall be collected as p art of 
the clinical trial and processed during and after trial completion.  
Personal data collected as part of the clinical trial will be transferred to/from the 
institution/investigator , LEO  and third parties acting on behalf  of LEO.  
Processing of personal data on behalf of LEO requires a written agreement between LEO and 
the relevant party which covers collection, processing and transfer of personal data in the 
clinical trial. In certain cases an agreement on transfer of personal data may also be requir ed. 
Investigators and LEO must ensure that collection, processing and transfer of personal data 
are in compliance with applicable legislation on data protection and privacy , including but no t 
limited to the EU General Data P rivacy Regulation . 
Subjects must be asked to consent to the collection, processing and tran sfer of their persona l 
data to EU and non -EU countries for the purpose of conducting the clinical trial, research an d 
development of new or existing products/service s, improving existing products/services, 
applying for marketing authorisations for products/services, marketing of products/services 
and other related activities.  
LEO has obtained the necessary authorisations for the processing of person al data collected i n 
the trial.  
Appendix 3D: Record keepi[INVESTIGATOR_007] , quality control,  and data handling  
Source d ata 
For all data recorded, the source document must be defined in a source document agreement 
or similar document at each trial site. There must only be 1 source defined at any time for an y 
data elements.  
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.[ADDRESS_621572] ’s medical record or other 
defined document normally used at the trial site. Source data not normally collected as a 
routine part of the clinical practice at the site may be entered on a worksheet. Clinical 
assessments/safety evaluations must be sig ned by [CONTACT_73347].  
If the worksheet does not become part of the subject ’s medical record, the following should as 
a minimum be added to the s ubject ’s medical record:  
Date(s) of conducti ng the informed consent process,  including date of
provision of subject information .
A statement from the investigator to verify that each of the eligibility criteria
are met  and documented .
Subject ID .
The fact that the subject is participating in a clinical trial in AD including
treatment with tralokinumab or placebo for 30 weeks .
Other relevant medical information .
Trial monitoring  
During the course of the trial , CRA(s)  will visit the trial site. These visits have the following 
objectives: (i) to continually verify source data to confirm that data entered into the eCRF by 
[CONTACT_18029], complete, and verifiable from source documents; (ii) to 
confirm that the safety and rights of subjects are being protected; and (iii) to confirm that the 
trial is being conducted in accordance with the currently approved protocol and any other trial 
agreements, ICH GCP, and all applicable regulatory requirements.  
The mon itoring visit intervals will depend on the  trial site ’s recruitment rate and the 
compliance of the trial site with the protocol and ICH GCP.  
In order to perform their role effectively, CRAs and persons involved in quality assurance and  
inspections will nee d direct access  to source data, e.g. medical records, laboratory reports,  
appointment books, etc. If the electronic medical record does not have a visible audit trail , the 
investigator must provide the CRA with signed and dated printouts. In addition, relevant site 
staff should be available for discussions at monitoring visits and between monitoring visits  
(e.g. by [CONTACT_756]).  
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.[ADDRESS_621573] safety. 
Risk reduction activities for the primary endpoint s include: 
Sourcing the vaccines to all participating trial sites.
Monitoring vaccine storage during the trial.
Ensuring a ccountability for each vaccine given to subjects.
Providing trial sites with a laboratory manual which explains how to collect
and process blood samples.
Using validated methods and a central laboratory to assess vaccine responses.
To ensure consistent d ata with respect to investigator assessment of efficacy (IGA, EASI and  
SCORAD), all investigators will receive training.  
Throughout the trial, data quality review meetings will be held to ensure that data collecti on 
can be improved and mistakes prevented.  During monitoring visits to the trial sites, CRA s 
will verify that investigators work according to the protocol.  
Data handling  
Data will be collected by [CONTACT_483643] (e.g., laboratory data). The investigator or staff authorised by [CONTACT_238525]-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.[ADDRESS_621574] verify the correctness of the data entered by [CONTACT_483644]. This signature [CONTACT_483653]. Any correction(s) made by [CONTACT_483645] t o 
the eCRF after original entry will be documented in the audit trail. Changes to data already  
approved will require the re -signature [CONTACT_3265] [CONTACT_093]. Th e person making the change to 
the data, and the date, time and reason for the change will be identified in the audit trail . 
Subject data should be entered into the eCRF no later than 5  working days after each visit , 
unless a different  deadline is stated in  the Clinical Trial Agreement. Queries for discrepant 
data will be generated automatically by [CONTACT_483646] , 
sponsor ’s medical expert,  or the data manager. All queries will be raised electronically wit hin 
the electronic data capture  system. This systematic validation will ensure that a clean and 
consistent database is provided for the statistical analysis.  
An ePRO solution will be used to  capture patient -reported data ( data from questionnaires 
completed at the trial site) . By [CONTACT_73357], data will be available immediately after 
data entry and available for monitors and site personnel, including the investigator, with read 
access only.  The ePRO system is a separate application from the eCRF and data captured 
from the eCRF and the ePRO will be stored on different servers during data capture. Data 
from both systems will be included in the final trial data base.  
External data transfers from vendors to LEO will be transmitt ed and handled via a secure file 
transfer protocol  site. Transmissions of electronic data from external data providers and of 
ePRO data to the clinical database are illustrated in Panel 14. 
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 111 of 123 
Panel 14: Transmission of electronic data  
CTR, clinical trial report; ECG, electrocardiogram; eC RF, electronic case report form; ePRO, 
electronic patient -reported outcome.  
Archiving of trial documentation  
The investigator at each trial site must make arrangements to  store the essential trial 
docu ments , including the investigator trial file (40). Essential trial documents must be stored 
until LEO informs the inve stigator that the documents are no longer to be retained , or longer 
if required by [CONTACT_427].  
In addition, the investigator is responsible for the archiving of all relevant source docume nts 
so that the trial data can be compared against source data  after the completion of the trial  (for 
example  in case of an inspection from regulatory authorities).  
The investigator is required to ensure the continued storage of the documents even if the 
investigator leaves the trial site or retires before the end of  the required storage period.  
No documents may be destroyed during the retention period without the written approval of 
LEO . No documents  may be transferred to another location or party without written 
acceptance from LEO . 
The destruction process must ensu re confidentiality of data and must be done in accordance 
with local regulatory requirements.  
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 112 of 123 
For archiving purposes, each inves tigator will be supplied with an electronic copy of the 
eCRFs and ePRO data for all screened and randomised  subjects at the tria l site. This is done 
after completion of the trial and before access to the eCRF/ePRO is revoked. Audit trail 
information will be included. eCRFs and ePRO data must be available for inspection by 
[CONTACT_82084], from regulatory authori ties and/or IRBs.  
Appendix 3 E: Registration, reporting and publication policy  
Trial disclosure  
LEO is committed to be transparent with respect to its clinical trials.  
Basic information of this clinical trial will be registered in  the global data registry, 
www.ClinicalT rials.gov before the first subject enters into the trial. The trial may also be come 
registered in other online data registries, according to applicable law and regulations.  
Results of this clinical trial will be post ed on the corporate website of LEO in accordance wi th 
LEO ’s Position on Public Access to Clinical  Trial Information no later than 12  months after 
trial completion. Trial r esults may also become reported in www. ClinicalTrials.gov, 
www.clinicaltrialsregister .eu and national data registries in accordance with applicable law  
and regulations after clinical trial completion or premature termination.   
LEO may also provide researchers access to anonymised patient level data for further 
research. Publication and access will be in accordance with LEO ’s Position on Public Access 
to Clinical Trials which can be found on LEO ’s website.  
Publications  
The investigator shall be entitled to make publications of the results generated by [CONTACT_483647] p rocess described here.  
A multi -centre publication will be  submitted for publication within [ADDRESS_621575] to th e following notice requirements:  
Prior to submission for publication o r presenting a manuscript relating to the clinical trial, the 
investigator shall provide to LEO a copy of all such manuscripts  and/or presentation s. LEO 
shall have rights  to review and comment. The i nvestigator shall consider LEO ’s comments 
but is not required to modify the manuscript and/or presentation based on such comments, 
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.[ADDRESS_621576] of LEO remove any confidential 
information (other than results generated by [CONTACT_093]) prior to submitting or presenting 
the manuscripts. The investigator shall, upon the request of LEO  withhold  the publication or 
presentation to allow LEO to protect its inventions and other inte llectual property rights 
described in any such manuscripts.  
In case no multi -centre publication has been made public at the time of investigator ’s 
notification  of an independent publication to LEO , LEO and the writing group may also delay 
the publication or presentation if the manuscript is deemed to harm the ongoing multi -centre 
publication.  
In case of publications made by [CONTACT_121630] -centre publication ha s 
been published, the above -mentioned requirements must still be followed.  
Any publication must comply with Good Publication Practice (GPP3) standards.  
LEO complies with GPP3 standards and the recommendations from the International 
Committee of Medical Journal Editors . LEO complies with the positions of the International 
Federat ion of Pharmaceutical Manufacturers & Associations (IFPMA), European Federation 
of Pharmaceutical Industries and Associations (EFPIA), Japan Pharmaceutical M anufacturers 
Association (JPMA), Pharmaceutical Research and Manufacturers of America (PhRMA) , and 
the joint position statement by [CONTACT_483648] (AMWA), the 
European Medical Writer s Association (EMWA), and the International Society for Medical 
Publication Professionals (ISMPP) on disclosure of information about clinical trials , trial 
results and authorship.  LEO also follows the Consolidated Standards of Reporting Trials 
(CONSORT ) reporting guidelines ( 22). 
Appendix 3 F: Insurance  
LEO has taken out relevant insurances covering the subjects in the present clinical trial in 
accordance with applicable laws and regulations.  
Appendix 3 G: Financial disclosure  
Investigators will provide LEO with sufficient, accurate financial information as reques ted to 
allow LEO to submit complete and accurate financial certification or disclosure statements to 
the appropriate regulatory authorities. Investigators are responsible for providing informat ion 
on financial interests during the course of the clinical trial and for 1  year after completion  of 
the clinical trial, or for a longer period of time if required by [CONTACT_19666].  
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 114 of 123 
Appendix 3 H: Trial  and s ite closure  
Premature termination of trial or trial site 
LEO, the inve stigator, the IRB s or competent authorities may decide to stop the clinical trial, 
part of the trial or a trial site at any time, but agreement on procedures to be followed must be 
obtained.  
If a clinical trial is suspended or prematurely terminated, the investigator must inform the 
subjects promptly and ensure appropriate therapy and follow -up. As specified by [CONTACT_44536], the investigator or LEO must promptly inform IRB s and provide a 
detailed written explanation. Relevant competent authorities must  be informed.  
The trial must be terminated if the perception of the benefit -risk ratio (judged from clinical 
signs and symptoms, (S)AEs and/or remarkable safety laboratory changes) becomes 
unfavourable for the continuation of the trial.  
Reasons for the ear ly closure of a trial site by [CONTACT_421510]:  
Failure of the investigator to comply with the protocol,  the requirements of the
IRB or local health authorities, LEO ’s procedures, or GCP guidelines.
Inadequate recruitm ent of subjects by [CONTACT_093].
Completion of trial  
Investigators will be informed when subject recruitment is to cease.  Screening activities will 
be stopped at a trial site when the total requested number of subjects for the clinical trial has 
been obtained, irrespective of the specific site ’s planned inclusion number.  
Trial sites will be closed upon trial completion. LEO will undertake arrangements for the 
collection and disposal of any unused trial material that the investigator is not required to 
keep in his/her files.  A trial site is considered closed when all required documents and trial 
supplies have been collected and a trial site closure visit has been performed.  
When the randomisation code has been broken, the investigators will receive information 
about the treatment allocation for the subjects randomised at their respective sites and will be 
asked to record this in the subject ’s medical record.  
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 115 of 123 
Appendix 3 I: Responsibilities  
The signatory investigator is responsible for the approval of t he clinical trial protocol  and 
the CTR on behalf of all clinical trial investigators and as agreed to in a Signatory Investigator 
Agreement.  
The nat ional coordinating investigator s are responsible for national issues relating to the 
clinical trial as agreed to in a National Coordinating Investigator [INVESTIGATOR_65908].  
Each participating investigator  is responsible for all aspects of the clinical trial conduct at 
his/her trial site as agreed  to in a Clinical Trial Agreement.  
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341 Date: 23-Apr-2018  Version: 1.0 
Page 116 of 123 
Appendix 4: Hanifin and Rajka (1980) diagnostic criteria for AD  
From Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol. 1980;92 
(Suppl):44 -47. 
Major Features : must have 3 or more of the following:  
Pruritus
Typi[INVESTIGATOR_22784]:
oFlexural lichenification or linearity in adults
oFacial and extensor involvement in infants and children
Chronic or chronically -relapsing dermatitis
Personal or family history of  atopy (asthma, allergic rhinitis, atopic dermatitis)
Minor Features:  should have 3 or more of the following:  
Xerosis
Ichthyosis, palmar hyperlinearity, or keratosis pi[INVESTIGATOR_22785]
Immediate (type 1) skin -test reactivity
Raised serum IgE
Early age of onset
Tendency toward cutaneous infections (especially S. aureus and herpes simplex) or
impaired cell -mediated immunity
Tendency toward non -specific hand or foot dermatitis
Nipple eczema
Cheilitis
Recurrent conjunctivitis
Dennie -Morgan infraorbital fold
Keratoconus
Anterior subcapsular cataracts
Orbital darkening
Facial pallor or facial erythema
Pi[INVESTIGATOR_80166]
Anterior neck folds
Itch when sweating
Intolerance to wool and lipid solvents
Perifollicular accentuation
Food intolerance
Course influenced by [CONTACT_483649]
White dermographism or delayed blanch
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 117 of 123 
Appendix 5: Guidance for anaphylaxis diagnosis  (24) 
The National Institute of Allergy and In fectious Diseases (NIAID) and Food Allergy and Anaphylaxis 
Network Guidance for Anaphylaxis Diagnosis (FAAN) define anaphylaxis as a serious allergic 
reaction that is rapid in onset and may cause death. They recognize 3  categories of anaphylaxis, with 
criteria designated to capture from 80% of cases (category  1) to >95% of all cases of anaphylaxis (for 
all 3 categories).  
Clinical criteria for diagnosing anaphylaxis  
Anaphylaxis is highly likely when any one of the following 3 criteria are fulfilled:  
1)Acute onset of an illness (minutes to several hours) with involvement of the skin, mucosal
tissue, or both (eg, generalized hives, pruritus or flushing, swollen lips -tongue -uvula)
AND AT LEAST ONE OF THE FOLLOWING:  
Respi[INVESTIGATOR_7798] (eg, dyspnea, wheeze -bronchospasm, stridor, reduced peak
expi[INVESTIGATOR_10229] [PEF], hypoxemia)
Reduced blood pressure (BP) or associated symptoms of end -organ dysfunction (eg,
hypotonia [collapse], syncope, incontinence)
2)Two or more of the following that occur rapi[INVESTIGATOR_17176] a likely  allergen for that
patient (minutes to several hours):
Involvement of the skin -mucosal tissue (eg, generalized hives, itch -flush, swollen
lips-tongue -uvula)
Respi[INVESTIGATOR_7798] (eg, dyspnea, wheeze -bronchospasm, stridor, reduced PEF,
hypoxemi a)
Reduced BP or associated symptoms (eg, hypotonia [collapse], syncope,
incontinence)
Persistent gastrointestinal symptoms (eg, crampy abdominal pain, vomiting)
3)Reduced BP after exposure to known  allergen for that patient (minutes to several hours):
Infan ts and children: low systolic BP (age specific) or greater than 30% decrease in
systolic BP
Adults: systolic BP of less than 90 mm Hg or greater than 30% decrease from that
person’s baseline
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 118 of 123 
Appendix 6: Short version of eligibili ty criteria  
This appendix provides a short form (maximum 200 characters) of each of the eligibility 
criteria  to be used when data are submitted  to the FDA . 
No. Inclusion criteria  
1 Written informed consent has been obtained prior to any protocol -related procedures  
2 Age 18 to 54 years, both included, at screening 
3 Diagnosis of AD (as defined by [CONTACT_483600] (1980) criteria for AD)  
4 History of AD for 1 year or more  
5 Subjects with inadequate response to treatment with topi[INVESTIGATOR_483592]  1 year 
before the screening visit or for whom topi[INVESTIGATOR_80145]  
6 AD involvement of 10% (or more) body surface area at screening and baseline 
(visit  3) according to component A of SCORAD    
7 An EASI score of 12 (or more) at screening and 16 (or more) at baseline  
[ADDRESS_621577] applied a stable dose of emollient twice daily (or more, as 
needed) for at least [ADDRESS_621578] dermatitis that is likely to interfere with the 
assessment of severity of AD  
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 119 of 123 
No. Exclusion criteria  
7 Use of tanning beds or phototherapy (NBUVB, UVB, UVA1, PUV A), within 6 weeks 
prior to randomisation  
8 Treatment with immunomodulating medications, systemic corticosteroids, or 3 or 
more bleach baths during any week within 4 weeks prior to randomisation  
9 Treat ment with the topi[INVESTIGATOR_483593], TCI or PDE -4 inhibitor within 2 weeks 
prior to randomisation  
10 Receipt of any vaccine within 3 months prior to screening, any meningococcal 
vaccine within 1  year prior to screening, or any tetanus-containing vaccine  within 
5 years prior to screening   
11 Receipt of any marketed or investigational biologic agents (e.g., cell -depleting agents 
or dupi[INVESTIGATOR_12458]) within 6 months prior to randomisation or until cell counts return to 
normal, whichever is longer  
12 Receipt of a ny investigational non -biologic agent within 5  half-lives prior to 
randomisation  
13 Receipt of blood products within 4 weeks prior to screening  
14 Major surgery within 8 weeks prior to screening, or planned in -patient surgery or 
hospi[INVESTIGATOR_483594] e trial period  
15 Known or suspected allergy or reaction to any component of the IMP formulation  
16 History of any active skin infection within 1 week prior to randomisation  
17 History of a clinically significant infection (systemic infection or serious  skin 
infection requiring parenteral treatment) within [ADDRESS_621579] taking antiretroviral medications  
24 History of chronic alcohol or drug abuse within 12  months prior to screening, or any 
condition associated with poor compliance as judged by [CONTACT_093]  
25 History of attempted suicide or at significant risk of suicide (either in the opi[INVESTIGATOR_483595] C -SSRS)  
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 120 of 123 
No. Exclusion criteria  
26 Any disorder which is not  stable and in the investigator ’s opi[INVESTIGATOR_451487], influence the findings of the trial, or impede the subject ’s ability 
to complete the trial  
27 Any abnormal finding which in the investigator ’s opi[INVESTIGATOR_483596], 
influence the results of the trial, or influence the subject ’s ability to complete the trial  
28 Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level 2.[ADDRESS_621580] (upper limit of normal) or more at screening  
[ADDRESS_621581] negative HBsAg and HBcAb  
30 Subjects who are not willing to abstain from donating blood and/or plasma f rom the 
time of informed consent and for 16 weeks (5 half -lives) after last dose of IMP  
[ADDRESS_621582] of the trial, or immediate family members of such individuals  
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 121 of 123 
Appendix 7: Contact [CONTACT_483650] , appointed CRA, sponsor ’s medical expert , 
vendors used in the trial, and national coordinating investigators  are provided to the trial sites 
as a separate contact [CONTACT_4111].  
Sponsor  
LEO Pharma A/S  (referred to as ‘LEO ’ or ‘the sponsor ’ in this clinical trial protocol) is the 
sponsor of the clinical trial:  
LEO Pharma A/S  
Industriparken 55  
DK-2750 Ballerup  
Denmark  
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 122 of 123 
Appendix 8: WHO model prescribing information for classification of 
topi[INVESTIGATOR_421434] - and high -potency TCS. TCS have 
been ranked in terms of potency into [ADDRESS_621583] potent ( Panel 15). Efficacy and side -effects are 
greates t with the Class  I ultra -high-potency preparations which should only be used for 
limited time periods (2 -3 weeks).  
Representative preparations by [CONTACT_483651] ( 41). These groups may vary 
depending on the formulation and concentration and should be considered approximate. In 
general, ointments are more potent th an creams or lotions. Potency is also increased when 
TCS are used under occlusive dressings or in intertriginous areas . 
Panel 15: Classification of topi[INVESTIGATOR_483597]  I Clobetasol propi[INVESTIGATOR_225332], 0.05%  
Diflorasone diacetate  Ointment, 0.05%  
High  II Amcinonide Ointment, 0.1%  
Betamethasone dipropi[INVESTIGATOR_352920], 0.05%  
Desoximetasone  Cream or ointment, 0.025%  
Fluocinonide  Cream, ointment, or gel, 0.05%  
Halcinonide  Cream, 0.1%  
III Betamethasone dipropi[INVESTIGATOR_225332], 0.05%  
Betamethasone valerate  Ointment, 0.1%  
Diflorasone diacetate  Cream, 0.05%  
Triamcinolone acetonide  Ointment, 0.1%  
Moderate  IV Desoximetasone  Cream, 0.05%  
Fluocinolone acetonide  Ointment, 0.025%  
Fludroxycortide Ointment, 0.05%  
Hydrocortisone valerate  Ointment, 0.2%  
Triamcinolone acetonide  Cream, 0.1%  
V Betamethasone dipropi[INVESTIGATOR_225334], 0.02%  
Betamethasone valerate  Cream, 0.1%  
Fluocinolone acetonide  Cream, 0.025%  
Fludroxycortide  Cream, 0.05%  
Hydrocortisone butyrate  Cream, 0.1%  
TMF-000043494 - Version 1. 0
Trial ID: LP0162 -1341  Date: 23-Apr-2018  Version: 1.0 
Page 123 of 123 
Panel  15: Classification of topi[INVESTIGATOR_11930] (continued)  
Potency  Class  Topi[INVESTIGATOR_421436]  V Hydrocortisone valerate  Cream, 0.2%  
Triamcinolone acetonide  Lotion, 0.1%  
Low VI Betamethasone valerate  Lotion, 0.05%  
Desonide  Cream, 0.05%  
Fluocinolone acetonide  Solution, 0.01%  
VII Dexamethasone sodium phosphate  Cream, 0.1%  
Hydrocortisone acetate  Cream, 1%  
Methylprednisolone acetate  Cream, 0.25%  
Source: WHO model prescribing information: drugs used in skin diseases ( 41). 
TMF-000043494 - Version 1. 0
Signature [CONTACT_1220]-000043494 v1.0
Signature [CONTACT_1220]-000043494 v1.0Reason for signing: Approved Manage Lead Approver Verdict(s)
Name: 
[CONTACT_483654]: 24-Apr-2018 12:34:53
GMT[PHONE_006]
Reason for signing: Approved Manage Approver Verdict(s)
Name: 
[CONTACT_121658] s
Date of signature: 24-Apr-2018 14:55:44
GMT[PHONE_006]
Reason for signing: Approved Manage ad Approver Verdict(s)
Name: 
[CONTACT_483655]: 24-Apr-2018 20:07:02
GMT[PHONE_006]
TMF-000043494 - Version 1. 0
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]